Search this site

Nelson Advisors: The Restructuring of UK Patient Engagement - NHS App Disintermediation, Direct EPR Integration and the Sunset of the Outpatient Model The National Health Service in England is executing a structural overhaul of its citizen facing digital channels. Driven by the strategic framework of the government’s 10-Year Health Plan (Fit for the Future) and informed by the operational diagnosis of the 2024 Darzi Review, the health service is transitioning away from a fragmented ecosystem of locally procured patient portals toward a centralised, state-curated "digital front door" anchored on the NHS App. This transition fundamentally alters the operational relationship between citizens, healthcare providers and health technology suppliers. By leveraging the Patient Care Aggregator (PCA), the technical broker engineered under the Wayfinder programme and establishing direct application programming interface (API) pipelines between acute Electronic Patient Record (EPR) systems and national infrastructure, NHS England is dis-intermediating the commercial market for standalone Patient Engagement Portals (PEPs). Simultaneously, the explicit policy commitment to phase out the traditional, hospital centric outpatient appointment model by 2035 is accelerating a system wide shift toward asynchronous digital triage, patient initiated follow-up (PIFU) and continuous remote care. These combined initiatives require Integrated Care Boards (ICBs), acute trusts and health technology vendors to adapt to a new paradigm defined by the decline of destination portals and the rise of "headless" clinical orchestration infrastructure. Strategic Hegemony of the National Digital Front Door England's strategic digital consolidation addresses a long-standing productivity paradox across the NHS: decades of localised capital investments in health technologies failed to yield macroeconomic efficiencies because solutions were deployed within isolated organisational and technical silos. The NHS App has evolved from a transactional tool, rapidly adopted during the COVID-19 pandemic to verify immunisation records, into a mandatory national platform connecting citizens to primary, secondary and community care services. The operational scale of this centralised infrastructure provides the distribution necessary to enforce market conformity across health systems and suppliers: Strategic Channel Indicator Current Operational Metric Policy Target / Trajectory Strategic Policy Reference Registered User Base 37.4 million citizens Ubiquitous adult population coverage National Digital Channels Strategy NHS Login Identities 43.0 million authenticated accounts Universal federated citizen identity NHS England Digital Framework Monthly App Logins 50.0 million monthly logins 100.0 million monthly logins 10-Year Health Plan Roadmap Adult Population Reach ~27% active monthly engagement Primary interface for care navigation National Performance Baseline Outbound Messaging Volume Scaled via NHS Notify platform 270.0 million digital notifications Digital Correspondence Strategy This national consolidation is driven by severe financial pressures. Under the 2025 Spending Review, which mandates an annual 2% operational efficiency gain alongside a 50% administrative expenditure reduction for Integrated Care Boards by March 2026, the historic practice of acute trusts independently licensing standalone, patient-facing software layers has become unsustainable. Standardising patient communications and outpatient navigation natively within the central NHS App shell yields an immediate recurring operational saving of approximately £11 million annually by removing duplicative software licenses and commercial support contracts. Centralisation also delivers substantial transactional savings across trust operating budgets. Providers migrating clinical correspondence from physical post to the NHS App and the NHS Notify messaging gateway have recorded a 97.8% reduction in carbon emissions and document production expenditures relative to paper communications. Automated push notifications are progressively replacing costly commercial SMS aggregators, reducing routine communication marginal costs to negligible levels while providing an authoritative single point of contact for patients. The Architecture of Disintermediation: Wayfinder and the Patient Care Aggregator The technical mechanism driving this market consolidation is the Patient Care Aggregator (PCA), developed under NHS England's Wayfinder programme. The PCA operates as a cloud-hosted, stateless query response broker that negotiates data exchanges between the front-end NHS App and disparate provider systems. Rather than assembling a massive, vulnerable central data repository of secondary care appointments, the PCA maintains secure record locators indexed to each citizen's NHS number. The operational pipeline functions through a coordinated sequence of synchronous API transactions: Aggregated Discovery via API 1: When an authenticated user launches the secondary care interface within the NHS App, the mobile client issues a Fast Healthcare Interoperability Resources (FHIR) query to the Patient Care Aggregator. Referral Collation via API 2: The PCA queries the national NHS e-Referral Service (e-RS) FHIR API to retrieve all active primary-to-secondary care referral items and pending bookings. Targeted Provider Polling via APIs 3 and 4: Rather than polling every hospital trust in England, the PCA references its internal Record Service (API 4), which receives advance notifications from secondary care booking systems regarding which patients they hold active records for. The broker then queries only those identified trust systems using the standardised Get Appointments API (API 3). Data Normalisation and Rendering: The PCA aggregates the disparate data payloads into a unified JSON structure containing appointment dates, times, healthcare organisations, specialties, consultation types, and actionable flags, rendering them natively within the NHS App user interface. Secure Transactional Handoff: For complex interactions that cannot yet be rendered natively, such as multi-resource scheduling, cancellations within restricted clinical windows, or specialty-specific pre-assessment forms, the PCA issues a deep link. Leveraging NHS Login as a federated single sign on mechanism, the NHS App passes an OAuth 2.0 token to launch an in-app WebView displaying the trust’s underlying booking system or questionnaire platform without requiring a secondary user login. The commercial consequence of this architecture is the deliberate disintermediation of commercial Patient Engagement Portals. NHS England announced that central funding for the Wayfinder national support programme will terminate by March 2026, signalling a policy pivot away from subsidised third party front ends. NHS England is systematically phasing out supplier managed front ends across five core functional capabilities: appointment scheduling, document distribution, outbound and inbound notifications, pre-visit questionnaires and initial triage. Architectural Layer Legacy Standalone Model (2015–2023) Wayfinder Aggregator Model (2024–2026) Target Single Patient Record Era (2027+) User Entry Point Multiple trust-specific portals and discrete vendor mobile applications. Unified national view in NHS App; WebView handoffs for complex tasks. Unified native presentation within the NHS App shell across all trusts. Authentication Fragmented local credentials, trust user accounts, and one-time SMS passcodes. Centralized NHS Login single sign-on with biometric authentication support. Universal biometric NHS Login integrated with the Single Patient Record. Data Topology Proprietary vendor cloud repositories holding replicated copies of PAS data. Stateless query broker dynamically polling endpoints via record locators. Direct FHIR interoperability and bi-directional write-back to native EPR stores. Commercial Role of PEPs Primary customer-facing destinations charging recurring per-patient fees. White-labeled form management (DQM) and secondary care bridging tools. Invisible "headless" orchestration engines and clinical pathway rules processors. Commercial software suppliers can no longer justify recurring licensing fees merely by providing consumer-facing user interfaces. By establishing direct relationships with over 37 million citizens, the national health service has effectively absorbed the consumer interface layer, pushing commercial vendors into commoditised back-end roles. Direct Electronic Patient Record Integrations: Bypassing the Intermediary The strategic transition from third party patient portals to direct EPR integration is supported by NHS England's Frontline Digitisation programme. By mid-2025, enterprise EPR adoption reached 91% across acute providers, with universal coverage mandated by March 2026. However, the national Digital Maturity Assessment revealed that while 93% of providers operated an enterprise EPR, only 30% had established bi-directional data exchanges across clinical pathways. Historically, hospital trusts procured commercial PEPs like DrDoctor, Patients Know Best and Induction Zesty to serve as translation layers between legacy Patient Administration Systems (PAS) and digital interfaces. Modern enterprise EPR platforms now provide direct, standards based integration hooks configured for national digital health infrastructure, making intermediary software layers redundant: Enterprise EPR Supplier Integration Mechanism Functional Capabilities Delivered to NHS App Verified Deployment Sites Epic Systems SMART on FHIR via App Orchard; native PCA interfaces Direct booking, clinical note access, pre-operative forms, Bedside MyChart Guy’s and St Thomas’, King’s College Hospital, UCLH, CUH, Devon ICS ("MY CARE") Oracle Health (Cerner) SMART on FHIR via Code Console; native REST APIs Bi-directional demographic query, letter suppression, slot rebooking ~55 NHS England trusts, including Barking, Havering and Redbridge Meditech Expanse SMART on FHIR via Greenfield API suite (v2.2) Longitudinal records, laboratory releases, documentation, oncology tracking Alder Hey Children’s NHS Foundation Trust (~12 secondary care installations) The Phoenix Partnership (TPP) Direct £960k capital contract for native PCA / BaRS integration Cross-care booking, appointments, community document access Humber Teaching NHS Foundation Trust (leading cohort of 11 SystmOne trusts) The clinical and economic impact of direct EPR integration is demonstrated by Epic deployments across London and the South West. Across Devon Integrated Care System, uniting Royal Devon University Healthcare, Torbay and South Devon, and University Hospitals Plymouth, a single enterprise Epic instance powers the "MY CARE" platform, connecting directly to the NHS App without third-party middleware. Similarly, deployments across King's College Hospital and Guy's and St Thomas' NHS Foundation Trusts illustrate the operational benefits of removing external intermediaries. By coupling direct NHS App integration with Epic Bedside MyChart inpatient tablets, these providers achieved a 38% adoption rate within one month of launch, saving over 24 hours of nursing administrative time per ward per month. Inpatient tracking of medication schedules, care plans and nurse communication flows straight into the primary clinical record, demonstrating that intermediary PEP software is no longer required to achieve high digital maturity. Outpatient Deconstruction and the Shift to Asynchronous Care Direct technical integrations coincide with a broader structural reform: the planned dismantling of the traditional NHS outpatient care delivery model. England’s healthcare system currently handles approximately 120 million outpatient appointments every year, with two thirds categorised as routine follow-up attendances, generating an annual expenditure exceeding £14 billion. The 2024 Darzi Review highlighted the operational inefficiency of this model, showing that consultant outpatient appointments per doctor fell by 7% relative to historical baselines. Clinicians and patients remain trapped in an analogue system of arbitrary 6- and 12-month calendar reviews that often fail to reflect active disease progression or improve health outcomes. In response, the 10-Year Health Plan sets a clear policy objective: to phase out the traditional hospital-based outpatient model by 2035. The Department of Health and Social Care’s Neighbourhood Health Framework establishes binding operational targets, requiring systems to divert at least 25% of elective outpatient referrals away from acute hospitals by March 2027, alongside a broader target to transition two-thirds of routine outpatient appointments to digital alternatives. This reform relies on four interconnected operational mechanisms that replace physical clinic visits with continuous, community based care: The first mechanism is the national launch of NHS Online in 2027. Operating through the NHS App, NHS Online allows primary care clinicians and automated triage systems to refer patients directly to national digital specialist teams for high-volume conditions such as suspected endometriosis or prostate enlargement, bypassing local hospital queues. The second mechanism is the expansion of Patient-Initiated Follow-Up (PIFU) across all elective specialties. Instead of routine calendar-based outpatient check-ups, stable patients monitor their symptoms at home and trigger clinical reviews through validated questionnaires in the NHS App only when symptoms flare. The third mechanism is the physical relocation of specialist consultations into 250 newly developed or upgraded Neighbourhood Health Centres, shifting multidisciplinary care out of acute hospitals and closer to local communities. The fourth mechanism is the deployment of continuous remote physiological monitoring and virtual wards, shifting the management of chronic respiratory, cardiovascular, and metabolic illnesses into the patient's home. Consequently, the role of patient engagement technology is shifting fundamentally. When care moves from scheduled clinic attendances to continuous digital monitoring, engagement software ceases to be a simple administrative notification tool. Instead, it becomes the clinical pathway itself, responsible for ingesting patient biomarkers, executing risk-scoring algorithms and managing asynchronous clinical workflows. Nelson Advisors: The Restructuring of UK Patient Engagement - NHS App Disintermediation, Direct EPR Integration and the Sunset of the Outpatient Model Dual National Data Architectures: The Single Patient Record Versus the Federated Data Platform The technical foundation supporting this new care model is the Single Patient Record (SPR), introduced in the 10-Year Health Plan and underpinned by the NHS Modernisation Bill announced in May 2026. The legislation shifts clinical data sharing from a local discretionary choice to a national obligation, establishing the statutory authority required to overcome data fragmentation across acute, community, and primary care. Healthcare leaders must distinguish between the Single Patient Record and the Federated Data Platform (FDP), as their architectures, governance, and operational goals are fundamentally different: Architectural Dimension Single Patient Record (SPR) Federated Data Platform (FDP) Core Functional Purpose Authoritative clinical "System of Record" for direct individual patient care and cross-boundary visibility. Operational orchestration engine and aggregate analytics platform for organizational capacity management. Underlying Architecture Federated query model connecting local EPRs, GP systems, and Shared Care Records via standardized FHIR profiles. Centralized software architecture (built on Palantir Foundry) ingesting trust data into local and national containers. Primary Deployed Modules Longitudinal consultations, unified medications, allergies, diagnostic results, and end-of-life care plans. Referral-to-Treatment (RTT) validation, Cancer 360, operating theatre scheduling, and OPTICA discharge management. Target User Base Patients accessing data via the NHS App, and clinicians delivering direct cross-boundary patient care. Trust operational managers, clinical discharge directors, bed coordinators, and ICB performance analysts. Statutory & Governance Basis NHS Modernisation Bill provisions mandating direct clinical data sharing across organizations. Commercial national procurement with local Data Protection Impact Assessments (DPIAs) and trust data sharing agreements. The Single Patient Record is not a massive, centralised data repository that replaces existing hospital software. Instead, it functions as a federated system of record that links local EPRs, primary care systems, and regional Shared Care Records through national interoperability standards. The SPR is scheduled for phased national deployment, delivering initial capabilities for frailty and maternity care in 2027 before expanding into a comprehensive summary record accessible via the NHS App by 2028. By 2035, the platform is targeted to ingest consumer wearable data and home diagnostics into a national "My Health" preventative console, transforming the patient into an active partner in their own care. In contrast, the Federated Data Platform (awarded to Palantir Technologies in 2023 and deployed across 77 operating trusts by late 2025) serves primarily as an operational management tool. While the FDP aggregates data to optimise hospital workflows, such as elective waiting list validation, operating theatre utilisation, and bed allocation, the SPR is focused on clinical transparency and direct care delivery. Aligning clinical write-backs from the NHS App with local EPR workflows, while coordinating operational analytics across the FDP, represents one of the most complex architectural integration tasks facing NHS digital leaders. The Future of Commercial Patient Portals: Headless Orchestration and Deep Specialty Care As native EPR integrations and the central NHS App commoditise basic appointment scheduling, messaging, and digital letter delivery, the market for standalone patient destination portals is drawing to a close. Commercial vendors cannot maintain SaaS subscription revenues purely by offering general purpose digital interfaces. To remain viable, leading health technology suppliers are pivoting toward "headless" Backend as a Service (BaaS) architectures. By decoupling complex clinical business logic from the user presentation layer, these vendors operate as specialised orchestration engines running in the background, while all patient interactions are surfaced natively within the NHS App interface via standardised APIs: Commercial Vendor Historical Market Stance Headless Architectural Realignment Differentiated Clinical Value Proposition DrDoctor Standalone appointment booking portal and outbound SMS notification engine. HybridOS: Headless orchestration platform connecting to 20+ legacy PAS/EPR cores via FHIR APIs. Advanced clinic capacity management, automated waiting list validation, conversational AI, and print suppression. Patients Know Best (PKB) Independent Personal Health Record (PHR) requiring dedicated citizen user logins. Embedded longitudinal data engine integrated with Regional Shared Care Records and NHS App. PRSB-aligned cross-boundary care planning, multi-source home diagnostics, and patient-held data governance. Induction Healthcare (Zesty) Patient portal for outpatient check-ins and appointment self-management. Embedded write-back engine operating directly within Oracle Health (Cerner) footprints. Deep bi-directional write-back to PAS clinic scheduling, complex sub-specialty rules, and slot re-allocation. Accurx Primary care SMS messaging utility and video consultation gateway. System-wide cross-boundary communication and clinical workflow documentation layer. Ambient AI clinical scribing, asynchronous multi-disciplinary team communications, and primary-secondary care integration. Surviving commercial vendors are focusing on specialised, high acuity clinical workflows that centralised national platforms cannot easily manage: Specialty pathway automation represents a primary area of differentiation. Longitudinal clinical monitoring requires complex tracking that standard national booking platforms cannot accommodate. For example, University Hospital Southampton’s My Medical Record platform orchestrates active surveillance for prostate cancer, inflammatory bowel disease monitoring, and post-discharge cardiac rehabilitation across 26 NHS trusts. These condition-specific pathways depend on nuanced clinical algorithms that evaluate ongoing symptoms and alert clinical teams when intervention is necessary. Perioperative pathway management offers another major focus for specialised platforms. Preparing patients for surgery requires automated clinical risk stratification, preoperative health assessments, medication management (such as protocols for antiplatelets and anticoagulants), and digital anesthetic screening. Specialized clinical engines gather this data, assess procedural risks, and route structured updates directly into hospital operating theatre management suites. Algorithmic waiting list validation is also critical for elective recovery. With millions of citizens on elective waiting lists, vendors deploy automated digital outreach to determine whether patients still require treatment. By dynamically assessing clinical need and filling late cancellations, these engines help reduce Did Not Attend (DNA) rates by up to 30%, freeing up clinical capacity across acute hospitals. Finally, the systematic collection of Patient-Reported Outcome Measures (PROMs) and Patient-Reported Experience Measures (PREMs) relies on tailored digital workflows. Capturing validated clinical instruments, such as Oxford Hip and Knee Scores or condition-specific oncology metrics, requires flexible form builders and automated scheduling engines that push questionnaires to patients at defined points in their recovery, feeding structured data back into hospital records. Strategic Frictions, Systemic Vulnerabilities and Delivery Realities While the consolidation of citizen-facing digital health services into the NHS App resolves historical market fragmentation, it introduces significant operational, structural, and clinical challenges that healthcare leaders must manage. The creation of a single national digital interface introduces a major architectural single point of failure (SPOF). Technical disruptions or API failures within the central Patient Care Aggregator infrastructure risk interrupting patient access and communication across dozens of acute trusts simultaneously. Furthermore, centralising interface decisions within national bodies can slow local digital innovation. When modifications to clinical pathways require national reviews and central development capacity, individual healthcare providers can struggle to adapt their digital services quickly to address local operational priorities. At the local level, acute trusts and Integrated Care Boards face a challenging financial transition. The termination of central funding for the Wayfinder programme by March 2026 coincides with mandatory 50% operational cost reductions across ICBs, leaving local healthcare leaders with difficult procurement choices. Local systems must decide whether to allocate scarce local funds to maintain specialised commercial clinical tools or rely exclusively on the baseline capabilities provided by the national NHS App. While relying solely on central tools reduces local software expenditures, it risks removing advanced perioperative pathways, custom specialty workflows and flexible digital communication tools that native EPRs and basic national interfaces cannot provide. The drive to divert 25% of elective outpatients by 2027 and phase out traditional outpatient models by 2035 also introduces significant health equity risks. A strict digital-first strategy risks worsening health inequalities in line with the Inverse Care Law, where older individuals, patients managing multiple complex conditions, and socioeconomically disadvantaged communities face substantial barriers to accessing digital care. If healthcare systems scale down physical outpatient clinics before establishing accessible community alternatives, digitally excluded groups risk falling out of regular clinical care. Preserving equitable healthcare access requires maintaining assisted digital routes, including dedicated support kiosks within Neighbourhood Health Centres and proactive administrative outreach, to ensure structural reforms do not widen health disparities. Finally, managing the technical relationship between the Single Patient Record and the Federated Data Platform creates considerable operational complexity for healthcare providers. Frontline acute trusts must manage data flows across two distinct national platforms that operate under different technical architectures, corporate partners, and legal governance frameworks. Ensuring that patient entered data from the NHS App writes back accurately into local EPR systems, while simultaneously reconciling data across the FDP and the SPR, represents a complex technical and governance challenge that will demand sustained attention from health informatics leaders over the coming decade. Conclusion: The Two-Tier Paradigm of UK Patient Engagement The model of the standalone, consumer facing hospital patient engagement portal in England is rapidly concluding. The UK health sector is establishing a two-tier digital engagement architecture: The top tier comprises a state curated, unified national front door delivered via the NHS App. Governing the user experience for more than 38 million citizens, this national layer standardises to the Single Patient Record. The foundation tier consists of a specialised clinical layer made up of enterprise EPRs and headless orchestration engines. Interfacing with national infrastructure through standard FHIR APIs and the Booking and Referral Standard (BaRS), these back-end platforms manage complex specialty care, perioperative pathways, dynamic capacity validation and continuous remote monitoring. Vendors and healthcare organisations that adapt to this division of responsibilities will be well positioned to support the three core shifts of the 10 Year Health Plan: moving care from hospitals into community settings, transitioning services from analogue to digital, and shifting healthcare delivery from reactive treatment to proactive prevention. Platforms that attempt to maintain standalone patient facing portals will find themselves increasingly marginalised by the continuous expansion of England's unified national digital health infrastructure. Nelson Advisors > European HealthTech, MedTech, Digital Health Investment Banking Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, MedTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, industry trends, deal commentary, market analysis & predictions @ https://www.healthcare.digital Nelson Advisors publish Europe's Leading Healthcare Technology Investment Banking Newsletter every week, join 5000+ HealthTech and MedTech subscribers today! https://lnkd.in/e5hTp_xb Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards, corporates, venture capital and private investors to maximise shareholder value and investment returns.www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech#MedTech#DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #FemTech#ConsumerHealth #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA#Canada#Commonwealth#CorporateDivestitures #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Nelson Advisors @ 2026 Events Digital Health Rewired > March 2026 > Birmingham, UK NHS ConfedExpo > June 2026 > Manchester, UK HLTH Europe > June 2026, Amsterdam, Netherlands HIMSS AI in Healthcare > July 2026, New York, USA Bits & Pretzels > September 2026, Munich, Germany World Health Summit 2026 > October 2026, Berlin, Germany HealthInvestor Healthcare Summit > October 2026, London, UK HLTH USA 2026 > October 2026, USA Barclays Health Elevate > October 2026, London, UK Web Summit 2026 > November 2026, Lisbon, Portugal MEDICA 2026 > November 2026, Düsseldorf, Germany Venture Capital World Summit > December 2026 Toronto, Canada Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, MedTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

Nelson Advisors: Your Body Is the Product - Why Wearables Investors Have Stopped Caring About the Device Exec Summary During the initial growth cycle of consumer wearable technology, venture capital allocations and equity valuations were tethered directly to consumer electronics benchmarks: industrial design, miniaturisation of components, unit shipment volume, and hardware gross margins. The contemporary investment thesis has decisively broken with this framework. Institutional capital, private equity sponsors, and Big Tech acquirers now regard consumer hardware as a low-margin, commoditised conduit. Physical rings, wristbands, and sensor-laden patches are structured as loss-leading access points whose principal commercial function is to capture, ingest, and monetize an uninterrupted stream of longitudinal biometric data. This strategic pivot reflects a broader economic transformation: human biological processes have been operationalised as a high margin, recurring asset class. Once raw physiological signals, photoplethysmography waveforms, heart rate variability, continuous interstitial glucose, peripheral skin temperature, and sleep architecture, are integrated into proprietary algorithmic pipelines, they unlock recurring software revenues, enable dynamic underwriting transformations in life and health insurance, and compress discovery timelines in pharmaceutical development. The consumer may purchase a personal wellness tracker, but in institutional capital markets, the human body itself has become the underlying product. The Commoditisation of the Form Factor: From Hardware Margins to Software Multiples The flight of institutional capital away from hardware stems from the rapid commoditization of sensor technology and physical components. Across the preceding decade, tri-axial accelerometers, photoplethysmography (PPG) optical arrays, skin temperature thermistors, and Bluetooth Low Energy (BLE) microcontrollers evolved into off-the-shelf commodities. Original design manufacturers and contract assembly partners in Asia can replicate consumer tracking form factors with minimal capital expenditure, eroding any long-term technological defensibility inherent to hardware engineering alone. Standalone hardware businesses face persistent operational head-winds, including substantial working capital requirements, supply chain volatility, inventory obsolescence, and cyclical 18-to-24-month replacement intervals. Because customer acquisition costs (CAC) recur with each discrete unit sale, standalone hardware makers experience acute margin compression when market categories mature, an economic dynamic that previously undermined pioneers like Jawbone and led to the acquisition of Fitbit by Alphabet. To overcome these structural constraints, venture investors shifted to valuing wearable enterprises through the lens of Software-as-a-Service (SaaS) and digital health metrics. This valuation arbitrage relies on the stark economic divergence between physical products and recurring software layers. Operating Metric Standalone Hardware Business Model Biometric Platform and Data Model Primary Revenue Driver Transactional, one-time device sales Annual/Monthly subscription fees and enterprise data licensing Gross Margin Range 30% to 40% 65% to 80%+ Revenue Predictability Volatile, seasonal, cyclical upgrade dependent High annual recurring revenue (ARR) visibility Defensibility and Moat Industrial styling and branding (vulnerable to erosion) Longitudinal physiological baselines and algorithmic network effects Public/Private Multiples 1.0x – 2.5x Enterprise Value / Revenue; 15x – 20x P/E 6.0x – 10.0x+ Enterprise Value / Revenue; 25x – 35x+ P/E Engagement Lifecycle Concludes at product delivery; dormant until upgrade Daily interactive logging, biological nudging, and habituation As detailed in the structural comparison above, companies that monetise ongoing data interpretation escape the compressed margins of consumer electronics. Venture capital returns depend heavily on valuation multiple expansion; investors favor businesses commanding revenue multiples of 6x to 10x over pure hardware manufacturers trading near 1x to 2x sales. This multiple expansion reflects the economic reality that algorithmic software layers generate superior gross margins while creating durable switching costs that deepen with every day of user data capture. The Architectural Pivot: Hardware as a Service and Algorithmic Moats The institutional push toward software driven valuation multiples prompted the emergence of the Hardware-as-a-Service (HaaS) delivery structure. Under this configuration, the physical tracker is repositioned not as a durable possession owned by the consumer, but as an active terminal through which proprietary analytical software is dispensed. WHOOP engineered one of the earliest full executions of this strategy in 2018 by discarding its $500 upfront device purchase model in favor of a subscription-only architecture. Members pay an ongoing fee of $20 to $30 per month or $199 to $359 annually to retain access to platform analytics, while the physical wristband is provided at no independent retail charge. Backed by institutional funding rounds, most notably a $200 million Series F financing round led by the SoftBank Vision Fund that lifted the enterprise to a $3.6 billion valuation, WHOOP proved that eliminating hardware-driven consumer pricing friction accelerates data asset accumulation. The primary operational imperative in this pure-subscription format shifts entirely to member retention. Because the manufacturer absorbs hardware production costs, component logistics, and upfront marketing expenses, financial unit-economic models indicate that a member must typically remain active for at least 24 consecutive months before lifetime value eclipses acquisition and subsidization overhead. To mitigate churn, the platform builds an algorithmic switching barrier: because recovery, daily cardiovascular strain, and sleep scores require months of continuous tracking to calibrate accurate physiological baselines, a departing subscriber must abandon their accumulated biological history, rendering substitution across competing platforms friction-heavy. Oura pursued a related hybrid architecture. Having initially established scale via direct-to-consumer hardware sales, Oura introduced a recurring monthly membership fee with its third-generation ring, effectively placing detailed sleep architecture, readiness analytics, and biometric tracking behind an ongoing paywall. Although Oura still derives approximately 80% of its top-line revenue from hardware unit sales and 20% from recurring software subscriptions, the continuous software layer radically upgraded the enterprise's long-term financial quality. To build institutional defensibility beyond consumer discretionary spending, Oura launched Oura for Business, licensing pooled biometric telemetry to commercial enterprises, elite athletic organizations, and medical researchers. In late 2024, Oura deepened this ecosystem strategy by securing a $75 million strategic investment from medical device leader Dexcom, establishing an integrated commercial bridge between smart rings and real-time metabolic telemetry. Within these operating models, physical hardware functions purely as the collection layer of a multi-tiered monetisation architecture. At the sensor tier, the physical apparatus captures continuous autonomic and metabolic telemetry, including photoplethysmography pulses, accelerometry, and interstitial fluid shifts. These signals flow immediately into the core analytics engine, which converts raw data into validated biometric indices such as sleep stage distributions, baseline deviations, and cardiovascular strain. This interpreted data powers two parallel revenue streams: a consumer-facing SaaS subscription that monetises personalised health optimisation and an enterprise pipeline that syndicates longitudinal data to commercial payers, clinical research organisations and institutional employers. Somatic Monetisation: Actuarial Underwriting, Digital Biomarkers and Biosensing Consumables While consumer app subscriptions provide baseline operating cash flow, the largest institutional capital inflows into wearable platforms target institutional data monetisation across life insurance, clinical research, and metabolic consumable markets. Dynamic Actuarial Underwriting and Behavioural Insurance Historically, health and life insurance underwriting has relied on static, retrospective actuarial calculations: applicant age, family medical history, smoking status, and episodic laboratory screenings. Wearable telemetry transitions this legacy framework into continuous, real-time behavioural risk assessment. Pioneered globally by Discovery Limited through its syndicated Vitality program and commercialised in partnership with major carriers including John Hancock and UnitedHealthcare, behavioural insurance programs subsidise consumer smartwatches and rings in exchange for access to live biometric streams. This framework creates dual advantages for underwriters. First, it mitigates adverse selection by attracting a demographic cohort that skews younger, more affluent, and fundamentally proactive regarding wellness behaviours. Second, continuous algorithmic feedback loops actively nudge policyholders toward lifestyle interventions that suppress aggregate claims incidence. By monitoring cardiovascular activity, step counts, and sleep regularity, insurance actuaries dynamically optimise reserve capital allocations, replacing static demographic risk pools with real-time risk ratings. Digital Biomarkers and Pharmaceutical Clinical Trials The institutional biopharmaceutical sector has integrated wearable biometric streams to address rising clinical drug trial development costs. The global digital biomarkers market was valued between $5.0 billion and $6.3 billion in 2024 to 2025 and is projected to expand to between $35.8 billion and $41.0 billion by 2034 to 2035, growing at a compound annual growth rate exceeding 20%. Wearable based digital biomarkers represent between 41% and 61% of this total market capitalisation. Pharmaceutical sponsors use continuous sensor streams to support decentralized clinical trials and generate Real-World Evidence (RWE). High-frequency physiological tracking detects micro-changes in baseline autonomic function, gait velocity, nocturnal scratch frequency, and tremor characteristics in neurodegenerative diseases like Parkinson’s. By deploying wearables as continuous clinical endpoint monitors, trial sponsors bypass the noise and attrition associated with infrequent, on site hospital assessments, dramatically accelerating trial completion times and reducing drug development overhead. Consumable Biosensors and the Metabolic Ingestion Engine The most commercially lucrative manifestation of the somatic asset model combines wearable technology with consumable medical chemistry. Historically, continuous glucose monitors (CGMs) developed by Dexcom and Abbott were restricted to prescription bound, insurance reimbursed populations managing Type 1 or insulin dependent Type 2 diabetes. During 2024, both companies unlocked the broader consumer wellness landscape by securing clearance from the US Food and Drug Administration (FDA) for over the counter (OTC) biosensors. Biosensor System Regulatory Classification Primary Target Demographic Commercial Distribution Strategy Sensor Mechanical Lifecycle Dexcom Stelo FDA 510(k) Clearance (March 2024) Adults with Type 2 diabetes not on insulin; pre-diabetes; wellness cohorts Direct-to-consumer online ordering and e-commerce platforms 15-day single-use biosensor expiration Abbott Lingo FDA 510(k) Clearance (May 2024) Healthy consumers pursuing metabolic coaching and lifestyle tracking Direct-to-consumer retail, consumer subscription, Amazon store 14-day single-use biosensor expiration Abbott Libre Rio FDA 510(k) Clearance (May 2024) Non-insulin Type 2 diabetes adult patients (18+) Direct retail pharmacy competition targeting non-insulin metabolic care 14-to-15-day single-use biosensor expiration These continuous metabolic monitors represent a structurally distinct hardware model. Unlike smart rings or wristbands, which remain functional for years, enzymatic biosensors physically expire every 14 to 15 days due to the biological exhaustion of the glucose oxidase catalyst on the subcutaneous filament. This built-in chemical expiration creates a recurring subscription loop: users pay between $49 and $90 per month out of pocket to replenish hardware components. The physical patch functions as a consumable cartridge, while the underlying value driver remains the longitudinal metabolic software feedback loop that guides dietary and lifestyle modifications. Platform Power and Regulatory Scrutiny: Big Tech Moats and the Erosion of HIPAA Arbitrage For hyperscale technology platforms like Apple, Google, and Samsung, wearable hardware operates as an ecosystem retention anchor. These conglomerates do not require wearable product divisions to optimize standalone profit margins. For Apple, an Apple Watch serves primarily to secure iPhone retention, defending high-margin Services revenue segments that deliver gross margins between 65% and 75%, compared to hardware product margins of roughly 35%. Wearables also serve as intake portals for personal health records, establishing deep ecosystem lock-in. When an individual amasses several years of continuous cardiovascular, sleep, and activity baselines within a proprietary operating system, the transaction friction of migrating to an alternative platform becomes prohibitive. The regulatory importance of this biometric concentration was highlighted during the European Commission’s antitrust review of Google’s $2.1 billion acquisition of Fitbit. Antitrust authorities raised acute market-distortion concerns, concluding that merging Fitbit’s deep physiological database into Google’s programmatic advertising machinery would reinforce insurmountable barriers to entry across online search and ad display markets. To secure merger clearance within the European Economic Area, Google committed to a binding ten-year regulatory framework overseen by an independent technical trustee. These conditions required Google to maintain a strict internal data silo separating Fitbit biometric records from ad platforms, preventing European user health telemetry from influencing ad targeting. Google was further required to maintain open and non-discriminatory access to core Android application programming interfaces (APIs) for rival third-party wearable manufacturers, ensuring that competitive hardware could connect and interoperate with Android smartphones without artificial latency or degraded utility. This landmark antitrust intervention established that regulatory authorities no longer view wearables as simple consumer gadgets, but as systemic data aggregation platforms capable of consolidating anti-competitive power. Simultaneously, the foundational legal architecture underlying the consumer health economy is undergoing structural reform. Historically, commercial wearable makers exploited a substantial regulatory loophole: the provisions of the US Health Insurance Portability and Accountability Act of 1996 (HIPAA) apply strictly to covered entities such as hospitals, physicians, healthcare clearinghouses, and formal health maintenance organizations. Commercial wellness trackers fall outside this statutory perimeter. Operating within this non-HIPAA zone, wearable platforms gathered, aggregated, and transferred consumer biometric records to marketing entities, ad platforms, and analytical data brokers with minimal direct healthcare compliance liability. This regulatory environment is tightening rapidly. The US Federal Trade Commission (FTC) has stepped into the enforcement void by interpreting its Health Breach Notification Rule (HBNR) to govern direct to consumer health applications and connected digital devices. Through repeated enforcement actions, the FTC has established that transmitting sensitive consumer physiological or reproductive telemetry to third party data brokers or programmatic advertising tracking pixels without affirmative, explicit consent constitutes an actionable breach of federal trade law. Concurrently, state level regulations, exemplified by Washington State's My Health My Data Act, have established strict opt-in consent mandates specifically targeting non-HIPAA health data and commercial biometric profiling. Beyond statutory frameworks, advancements in analytical computing are undermining standard anonymisation claims. Modern data science demonstrates that continuous, high-frequency biological waveforms are virtually unique to the individual. When an anonymised telemetry stream containing granular heart rate accelerations, sleep wake cycles, and peripheral motion is cross-referenced with public geolocation metadata, individuals can be re-identified with high mathematical precision. These analytical realities have led academic observers and economic theorists to categorize consumer wearables as instruments of biological surveillance and "somatic capitalism". In this framework, human biological rhythms, historically insulated from financial markets, are systematically extracted, algorithmicised and monetised to support corporate risk governance, creating an asymmetrical exchange where consumers fund the acquisition of devices that harvest their biological data for institutional exploitation. Nelson Advisors: Your Body Is the Product - Why Wearables Investors Have Stopped Caring About the Device Strategic Horizon: The Post-Device Era The commercial evolution of wearable technology is rapidly entering a post-device phase. Sensor arrays are becoming increasingly ambient, disappearing directly into smart fabrics, continuous transdermal patches, audio hearing devices and consumer eyewear. As component miniaturisation renders the physical housing effectively invisible, the mechanical product will carry zero standalone consumer surplus. Venture capital allocation confirms that enduring equity value resides entirely within the machine learning models trained on these continuous somatic streams. Large scale physiological foundation models are being built to recognise early autonomic anomalies, metabolic dysregulation and neurodegenerative decline months before clinical symptoms manifest. The primary competitive battleground across the digital health industry will not be contested over industrial hardware design or wristband aesthetics. Market leadership and sustained capital returns will belong to the platforms that control the analytical interpretation layer, the digital infrastructure that ingests continuous bodily outputs, synthesises them into actionable behavioural insight and integrates them across clinical health systems, dynamic actuarial underwriters and automated AI health coaches. The wearable device has fulfilled its purpose as an initial distribution vehicle; the continuous biometric stream of the human body is the permanent asset. Nelson Advisors > European HealthTech, MedTech, Digital Health Investment Banking Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, MedTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, industry trends, deal commentary, market analysis & predictions @ https://www.healthcare.digital Nelson Advisors publish Europe's Leading Healthcare Technology Investment Banking Newsletter every week, join 5000+ HealthTech and MedTech subscribers today! https://lnkd.in/e5hTp_xb Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards, corporates, venture capital and private investors to maximise shareholder value and investment returns.www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech#MedTech#DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #FemTech#ConsumerHealth #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA#Canada#Commonwealth#CorporateDivestitures #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Nelson Advisors @ 2026 Events Digital Health Rewired > March 2026 > Birmingham, UK NHS ConfedExpo > June 2026 > Manchester, UK HLTH Europe > June 2026, Amsterdam, Netherlands HIMSS AI in Healthcare > July 2026, New York, USA Bits & Pretzels > September 2026, Munich, Germany World Health Summit 2026 > October 2026, Berlin, Germany HealthInvestor Healthcare Summit > October 2026, London, UK HLTH USA 2026 > October 2026, USA Web Summit 2026 > November 2026, Lisbon, Portugal MEDICA 2026 > November 2026, Düsseldorf, Germany Venture Capital World Summit > December 2026 Toronto, Canada Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, MedTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

Nelson Advisors: Specialists in European HealthTech, MedTech, Healthcare AI and Digital Health. Partnerships, Investments, Mergers & Acquisitions from $25M to $250M Enterprise Value A market in structural realignment The European healthcare technology M&A landscape is undergoing a structural realignment, and it is happening quietly. There is no single headline moment to point to, no dramatic collapse or blockbuster deal that marks the shift. Instead, the change has been cumulative: a gradual hollowing out of specialist advisory capacity in precisely the part of the market where most European HealthTech and MedTech companies actually live. At the top of the market, bulge bracket institutions have concentrated their healthcare franchises on billion-euro mega deals. The economics of a global bank make this inevitable. When a deal team's cost base is calibrated to transactions with fees measured in tens of millions, a €60M sale of a digital therapeutics business or a €120M carve-out of a connected device platform does not clear the internal hurdle, however interesting the asset may be. These businesses receive polite interest, perhaps an introductory call, and then a gentle redirection elsewhere. In the middle of the market, generalist mid-market banks face a different problem. They have the appetite for transactions of this size, but healthcare technology is a difficult sector to advise on without deep domain fluency. A clinical-grade software product is not a SaaS business with a medical label attached. A medical device with an embedded AI algorithm is not simply hardware with software features. Regulatory pathways, reimbursement dynamics, evidence generation, data governance, clinical validation and the peculiar buying behaviour of health systems all shape valuation in ways that a generalist technology framework cannot capture. Buyers know this. Boards know this. Founders learn it, sometimes painfully, when a process stalls because the adviser could not articulate why an asset was worth what its owners believed it to be worth. Between these two forces, a distinct gap has opened in the lower to mid market, the $25M to $250M Enterprise Value band that represents the vast majority of European healthcare technology companies by number. This is where founder-led businesses reach the point of a strategic decision. This is where venture-backed companies seek their next stage of growth capital or a strategic home. This is where corporate development teams at global MedTech and pharma groups look for the acquisitions that will renew their portfolios. And this is where the demand for specialist advice has consistently outstripped the supply. Nelson Advisors was built for exactly this segment. Not adapted to it, not stretched to cover it as an afterthought, but purpose built from the outset to serve European HealthTech, MedTech, Healthcare AI and Digital Health companies in the lower to middle market with the depth of sector expertise that these transactions demand. Sector exclusivity as a strategic choice The decision to be sector exclusive is the single most important choice Nelson Advisors has made, and it deserves some explanation because it runs against the instincts of most advisory businesses. The conventional logic of a boutique investment bank is to diversify. A firm that advises across technology, business services, consumer and industrials can weather a downturn in any one sector and can draw on a wider pool of potential mandates. Sector exclusivity, by contrast, concentrates risk. When healthcare technology valuations compress, as they did through parts of the post-pandemic reset, an exclusive healthcare technology adviser feels it directly. Nelson Advisors accepted that trade-off deliberately, because the alternative would have compromised the one thing that matters most to the founders, investors and boards it serves: the ability to price, position and sell a clinical asset with complete credibility. Sector exclusivity means that every conversation the firm has, every buyer relationship it maintains, every piece of market intelligence it gathers and every transaction it executes compounds within the same domain. When a Nelson Advisors team member speaks with the corporate development function of a global medical device group, they are continuing a relationship rather than starting one. When they build a valuation framework for a remote patient monitoring business, they are drawing on comparable transactions they have seen first-hand, not on a database extract. When they advise a board on the likely regulatory posture of a strategic acquirer toward a Software as a Medical Device product, they are speaking from direct experience of how those acquirers actually behave in diligence. This depth is difficult to replicate. A generalist firm can hire a healthcare specialist, but that individual sits within an organisation whose systems, relationships and instincts are calibrated to other sectors. An exclusive firm is calibrated to healthcare technology from the ground up. Over time, that calibration becomes a form of institutional knowledge that clients can feel in the quality of advice they receive. Founding Partners who have lived the founder's journey Reputation in advisory work is earned through outcomes, but it begins with credibility, and the credibility of Nelson Advisors rests first on the experience of its Founding Partners, Lloyd Price and Paul Hemings. Since 2012, Lloyd and Paul have built, scaled and sold four HealthTech businesses. These were not passive investments or board seats held at a distance. They were operating ventures in which the Founding Partners were directly responsible for product strategy, commercial execution, fundraising, team building and ultimately the exit process itself. The four exits span four distinct corners of the healthcare technology landscape: Patient Engagement, Medical Device Cybersecurity, Metabolic Health and Consumer Healthcare. Each of these markets taught something different. Patient Engagement exposed the realities of selling into health systems, where procurement cycles are long, clinical champions are essential and the gap between a pilot and an enterprise contract can swallow a company's runway. Medical Device Cybersecurity revealed how regulatory pressure creates markets almost overnight, and how strategic acquirers value capabilities that close compliance gaps in their own portfolios. Metabolic Health demonstrated the power of outcomes data in a market crowded with wellness claims, and the premium that acquirers place on evidence over marketing. Consumer Healthcare showed how direct-to-consumer economics interact with clinical credibility, and how brands that manage to hold both can command valuations that pure consumer or pure clinical businesses cannot. The cumulative effect of these experiences is an advisory perspective that is unusual in investment banking. Most bankers have never sat on the founder's side of a term sheet negotiation. Most have never had to decide whether to accept a lower headline price with cleaner terms or hold out for a higher number with more earn-out risk. Most have never felt the particular pressure of a process that is running while the business still has to hit its quarterly numbers, retain its key engineers and keep its clinical partners engaged. Lloyd and Paul have done all of this, four times over. When they advise a founder on how to structure a sale, they are drawing on decisions they made themselves, with their own equity at stake. When they tell a board that a particular buyer is likely to retrade on price after diligence, they are recognising a pattern they have encountered directly. When they counsel patience in a process, or urgency, the advice carries the weight of lived experience rather than theoretical models. This is the foundation of the firm's reputation amongst founders. Founders talk to one another, and the consistent message that emerges from those conversations is that Nelson Advisors understands the founder's position from the inside. That understanding is not a marketing claim. It is a matter of record. A team built from the best of banking, science and operating experience The Founding Partners set the tone, but the Nelson Advisors team as a whole is what delivers transactions. The firm has assembled a group of Directors and Analysts whose backgrounds combine the rigour of top-tier investment banking with scientific depth and hands-on operating experience in healthcare. On the banking side, the team includes professionals whose careers were shaped at Rothschild, Citi and Morgan Stanley. These institutions instil a particular discipline in transaction execution: the construction of an information memorandum that anticipates every buyer question, the management of a competitive process that maintains tension without alienating serious bidders, the negotiation of a share purchase agreement in which the warranties, indemnities and earn-out mechanics are understood as deeply as the headline price. This discipline is what distinguishes a well-run process from a merely adequate one, and it is what allows Nelson Advisors to bring bulge bracket execution standards to transactions that bulge bracket banks will not touch. On the scientific and investment side, the team draws on experience from ETH Zurich, one of Europe's leading technical universities, and from Kieger and redalpine, investors with deep roots in Swiss and European healthcare and technology venture capital. This experience matters because so many of the assets Nelson Advisors advises on are, at their core, scientific propositions. An adviser who can read a clinical study, understand the statistical power of a trial, evaluate the defensibility of an algorithm or assess the regulatory strategy of a device company is an adviser who can engage with buyers on their own terms. The venture perspective adds a further dimension: an understanding of how investors think about stage, risk and return, which is invaluable when a transaction involves growth capital or a partial exit alongside a strategic partnership. On the operating side, the team includes professionals who have worked within Ethicon, Johnson & Johnson and Bristol Myers Squibb. This corporate experience is perhaps the least visible but most consequential element of the firm's capability. Global MedTech and pharma organisations have their own logic: their own strategic planning cycles, their own criteria for business development, their own internal politics around acquisitions and their own way of conducting diligence. Team members who have sat inside these organisations understand how a proposed acquisition moves through a corporate development committee, what a business unit leader needs to see to sponsor a deal and where the friction points lie. That understanding shapes how Nelson Advisors positions assets to strategic buyers and how it anticipates the questions that will arise long before they are asked. Across the team, academic achievement is consistently high. The firm's professionals hold MBAs, MScs and PhDs, and the combination of these qualifications with decades of aggregate experience in investment banking, financial analysis, investor relations and entrepreneurial ventures produces a rare blend. It is a team that can build a discounted cash flow model, interpret a regulatory submission, brief a board on investor sentiment and negotiate a deal, all within the same engagement and often within the same meeting. Nelson Advisors: Specialists in European HealthTech, MedTech, Healthcare AI and Digital Health. Partnerships, Investments, Mergers & Acquisitions from $25M to $250M Enterprise Value Reputation amongst investors Founders are one constituency. Investors are another, and their assessment of an adviser is shaped by different priorities. Venture capital and growth equity investors in European healthcare technology have, over the past several years, become increasingly discerning about the advisers they work with. The reason is simple: an exit process is the moment at which years of capital and effort are converted into returns, and the quality of that process has a direct effect on fund performance. An adviser who runs a poorly targeted process, mis-prices the asset or fails to maintain competitive tension can cost an investor a meaningful portion of their return on a position. Nelson Advisors has earned the confidence of investors by treating every process as an exercise in precision. Buyer identification is the first test. In healthcare technology, the universe of credible acquirers for any given asset is narrower than in generalist technology, and it is also more heterogeneous. A digital health platform might attract interest from a global MedTech group seeking a software layer, a pharmaceutical company building a patient services capability, a health insurer looking to reduce claims cost, a private equity firm consolidating a category, or a larger digital health company pursuing a roll-up strategy. Each of these buyer types values the asset differently, conducts diligence differently and structures deals differently. An adviser who understands these differences can construct a process that surfaces the best possible outcome. An adviser who does not will default to a generic approach that leaves value on the table. Investors also value candour. One of the recurring themes in the firm's investor relationships is that Nelson Advisors will tell a board what it needs to hear rather than what it wants to hear. If an asset is not ready for a sale process, the firm will say so and explain what needs to change. If a valuation expectation is unrealistic given current market conditions, the firm will present the evidence rather than simply accept the mandate and hope for the best. This can occasionally cost the firm an engagement in the short term. Over the long term, it is precisely what builds the trust that leads investors to return with their next portfolio company. The firm's activity in growth investments and partnerships, alongside pure M&A, adds a further dimension to its investor relationships. Not every transaction in the lower to mid market is an outright sale. Many companies at the $25M to $250M scale are seeking a strategic partner, a minority investment from a corporate, or a structured growth round that positions them for a larger exit in several years' time. Nelson Advisors advises across this full spectrum, which means that investors can engage the firm at multiple points in a portfolio company's lifecycle rather than only at the end. Reputation amongst boards The third constituency is the board, and here the firm's reputation rests on governance and judgement. Boards of healthcare technology companies carry a particular burden. They are often composed of a mix of founders, investor representatives, independent directors with clinical or commercial backgrounds and, in some cases, representatives of strategic shareholders. Their interests are aligned in principle but frequently diverge in practice, especially when a strategic decision is on the table. The founder may want to continue building. An early investor may want liquidity. A later investor may want to hold for a larger exit. An independent director may be concerned about execution risk in either direction. An adviser to a board in this situation must be able to do several things at once: present a clear and objective analysis of the strategic options, help the board understand the likely outcomes of each, facilitate a decision that all stakeholders can support and then execute that decision with discipline. This requires a combination of analytical rigour, interpersonal judgement and an understanding of governance that goes beyond transaction mechanics. Nelson Advisors has cultivated this capability deliberately. The firm's approach to board advisory begins with a strategic review rather than a pitch. Before recommending a course of action, the firm works with the board to understand the company's position, the market context, the shareholder dynamics and the realistic range of outcomes. This work is often the most valuable part of an engagement, because it gives the board a shared factual foundation on which to make a decision. Once that decision is made, the firm's execution discipline takes over, but the foundation of trust has already been established. Boards also value the firm's independence. Because Nelson Advisors is not part of a larger financial institution, it has no competing interests in lending, trading or asset management that might colour its advice. Its only interest is in delivering the best outcome for its client. This is a simple proposition, but it carries considerable weight with directors who have experienced the conflicts that can arise within larger institutions. Contributing to the next generation One element of the firm's identity that sits outside its transaction work, but is inseparable from its reputation, is the commitment of the Founding Partners to education. Lloyd and Paul regularly mentor MBA students and guest lecture at leading business schools across the UK and Europe, including University College London's Global Business School for Health, the University of Oxford, the University of Cambridge, London Business School and IESE Business School in Barcelona. These engagements cover the practical realities of building, funding and selling healthcare technology companies: how to think about market entry in a regulated sector, how to structure a cap table that survives multiple funding rounds, how to prepare a business for an exit and how the M&A process actually unfolds from the inside. This work is not incidental to the firm's business. It reflects a belief that the European healthcare technology ecosystem benefits when its future founders, investors and executives understand the full arc of a company's life, including the strategic transaction that so often marks its transition to a larger platform. It also keeps the Founding Partners in close contact with the emerging generation of talent in the sector, many of whom go on to found or join the companies that will become the firm's clients and counterparties in years to come. The relationships that emerge from mentoring and lecturing are long-term by nature. A student who attends a guest lecture at UCL's Global Business School for Health or a workshop at IESE may not need an adviser for a decade. When they do, they will remember who took the time to explain how the market works when there was no transaction to be had. This is reputation built patiently, in the way that reputation in advisory work must be built. What the lower to mid market actually needs It is worth returning to the structural gap described at the outset, because the firm's positioning within it is what makes the rest of its capabilities relevant. The lower to mid market in European healthcare technology is not a scaled-down version of the large-cap market. It has its own characteristics. Companies at this scale are often still founder-led, with founders who hold significant equity and strong views about the future of the business. They are frequently venture-backed, with investor syndicates that span multiple funds and multiple geographies. They operate in a regulatory environment that differs across the UK, the EU and the various national health systems within it. They sell into buyers, whether health systems, payers, pharma companies or consumers, whose purchasing behaviour is idiosyncratic and slow. And they are valued by acquirers who are themselves diverse: global strategics, mid-cap consolidators, private equity sponsors and, increasingly, larger digital health companies with their own acquisition strategies. Serving this market well requires an adviser who can engage with all of these dimensions. It requires a firm small enough to give senior attention to every mandate, but capable enough to run a competitive international process against well-resourced buyers. It requires sector knowledge deep enough to price clinical and regulatory risk accurately, and commercial judgement sharp enough to recognise when a buyer's interest is real. It requires the ability to advise on partnerships and investments as well as outright sales, because the optimal path for a company at this scale is not always a sale. And it requires a reputation that gives founders, investors and boards the confidence to entrust the firm with the most important transaction in a company's history. Nelson Advisors has built its practice around these requirements. The firm's sector exclusivity ensures depth. The Founding Partners' four exits ensure empathy with the founder's position. The team's blend of banking, scientific and operating backgrounds ensures execution quality and buyer fluency. The firm's independence ensures objectivity. And its commitment to the wider ecosystem, through mentoring and teaching, ensures that its relationships extend well beyond the transactions it advises on today. Looking ahead The realignment of the European healthcare technology M&A market is unlikely to reverse. The forces that created the gap in the lower to mid market are structural: the cost base of large institutions, the difficulty of generalist banks in mastering clinical assets, and the sheer number of European HealthTech and MedTech companies that will reach a strategic inflection point over the coming years. If anything, these forces are intensifying as Healthcare AI matures from experimental pilots into commercially deployed products with real revenue and real regulatory scrutiny, as Digital Health consolidates after a period of fragmentation, and as global MedTech groups renew their portfolios through acquisition rather than internal development alone. For founders considering their options, for investors planning exits, and for boards weighing strategic alternatives, the choice of adviser will increasingly determine the outcome. The difference between a process run by a firm that understands healthcare technology from the inside and one run by a firm that is learning the sector on the client's time is not marginal. It is measured in valuation, in deal certainty, in the quality of the strategic partner secured and in the time and energy that management is able to devote to running the business while the process unfolds. Nelson Advisors exists to close that gap. Sector exclusive, founder-informed, institutionally rigorous and independent, the firm is emerging as the specialist investment banking partner for European healthcare technology in the $25M to $250M Enterprise Value range, where the majority of the sector's companies live and where the need for genuine expertise has never been greater. Nelson Advisors > European HealthTech, MedTech, Digital Health Investment Banking Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, MedTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, industry trends, deal commentary, market analysis & predictions @ https://www.healthcare.digital Nelson Advisors publish Europe's Leading Healthcare Technology Investment Banking Newsletter every week, join 5000+ HealthTech and MedTech subscribers today! https://lnkd.in/e5hTp_xb Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards, corporates, venture capital and private investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech#MedTech#DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #FemTech#ConsumerHealth #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA#Canada#Commonwealth#CorporateDivestitures #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Nelson Advisors @ 2026 Events Digital Health Rewired > March 2026 > Birmingham, UK NHS ConfedExpo > June 2026 > Manchester, UK HLTH Europe > June 2026, Amsterdam, Netherlands HIMSS AI in Healthcare > July 2026, New York, USA Bits & Pretzels > September 2026, Munich, Germany World Health Summit 2026 > October 2026, Berlin, Germany HealthInvestor Healthcare Summit > October 2026, London, UK HLTH USA 2026 > October 2026, USA Barclays Health Elevate > October 2026, London, UK Web Summit 2026 > November 2026, Lisbon, Portugal MEDICA 2026 > November 2026, Düsseldorf, Germany Venture Capital World Summit > December 2026 Toronto, Canada Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, MedTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

Nelson Advisors: The Industrialisation of Clinical and Administrative Labour - Deconstructing the Autopilot Playbook in Healthcare Julien Bek’s thesis, "Services: The New Software," argues that the next generation of decacorn and trillion dollar technology companies will not sell software tools to knowledge workers; instead, they will sell the completed work product directly, operating as software companies masquerading as services firms. Across the broader macroeconomic landscape, enterprises allocate approximately six dollars to human professional services for every single dollar spent on software. In healthcare delivery, this economic imbalance is magnified to an extreme degree. Hospital operating margins are perpetually constrained by clinical, operational and administrative labour, which collectively account for 55% to 65% of total hospital operating expenses, while enterprise information technology (IT) budgets remain firmly anchored between 3% and 5%. Traditional enterprise Software as a Service (SaaS) business models have reached operational saturation within health systems. Point solutions and Electronic Health Record (EHR) add-ons aggressively compete for marginal fractions of constrained IT capital, forcing digital health vendors into protracted procurement cycles, enterprise committee evaluations, and vendor consolidation initiatives. By shifting the commercial target from the software budget to operational and clinical labor line items, the autopilot model fundamentally restructures healthcare economics. Autopilots replace per-seat software licenses with outcome-based deliverables, transforming variable human wage costs into scalable, high-margin algorithmic workflows. However, healthcare is not an ordinary services vertical. Applying the autopilot playbook to medicine reveals distinct structural dynamics: a strategic wedge located in heavily outsourced administrative bottlenecks, an innovator’s dilemma that constrains first generation clinical copilots, an operational progression along a judgment to intelligence continuum and profound regulatory, tort and actuarial barriers that will dictate the terminal market structure of the AI native health system. Macroeconomic Foundations: The Labour to Software Disparity The foundational premise of the autopilot thesis is budget arbitrage: capturing enterprise capital earmarked for human labour rather than software tooling. In traditional enterprise software, a vendor licenses a tool to an internal employee for a monthly fee, leaving the client enterprise to bear the fully burdened labor cost of the professional executing the work. In healthcare, this division creates severe financial distortion. Health systems routinely spend tens of millions of dollars annually on outsourced administrative labor, business process outsourcing (BPO) agencies, clinical documentation improvement specialists, and third-party medical coders, while hospital Chief Information Officers face constrained capital budgets. Economic Dimension Enterprise SaaS Model (Copilot / Point Solution) Autopilot Services Model (AI Native Managed Service) Target Budget Category Discretionary IT Operating Budget (3% to 5% of Net Patient Revenue) Administrative & Operational Labor Spend (55% to 65% of Operating Expenses) Pricing Architecture Per-seat / Per-provider monthly license ($300 to $1,000 per seat per month) Outcome-contingent (Percentage of collections, fee-per-cleared-claim, fee-per-enrolled-trial-patient) Procurement Stakeholder Chief Information Officer (CIO) / Chief Medical Information Officer (CMIO) Chief Financial Officer (CFO) / VP of Revenue Cycle / Chief Operating Officer (COO) Value Realisation Mechanism Theoretical labor productivity gain (contingent on clinician compliance) Finished work product (clean claim, prior authorization approval, verified clinical cohort) Vendor Displacement Displaces incumbent point software applications or digital health tools Displaces offshore BPO vendors, domestic staffing agencies, and internal administrative overhead Unit Economics at Scale Margins capped by enterprise SaaS multiples and software seat churn Software gross margins (75% to 85%) captured on top-line healthcare service fee schedules The core flaw of enterprise health software over the past two decades has been its reliance on human execution to unlock economic return. Software platforms digitise records and structure data, but they externalise the cognitive labor back onto clinicians and administrative personnel, driving widespread clinician burnout and administrative overhead. When an AI company sells an outcome rather than a tool, every iteration of underlying foundation model capability expands the vendor's gross margin and processing velocity. The hospital Chief Financial Officer does not evaluate this purchase as an IT procurement; it is structured as an operational vendor swap that reduces administrative cost to collect and eliminates back-office labor overhead. The Administrative Wedge: High Velocity Outsourcing Substitution Per the Bek framework, autonomous systems establish an enterprise foothold where tasks satisfy three prerequisite conditions: the work is already outsourced, the cognitive burden is intelligence-heavy (governed by deterministic rules) rather than judgment heavy, and the final output is objectively verifiable. In healthcare, hospital networks and life sciences sponsors have spent decades establishing outsourced budget lines to external vendors. These friction points serve as the initial wedge for autonomous platforms. Operational Domain Domestic Labour TAM Incumbent Model Displaced Autopilot Delivery Model Representative Market Operators Medical Coding & Revenue Assurance $50B to $80B Offshore BPO firms, in-house certified professional coders (CPCs) End-to-end chart-to-claim generation; contingency billing (% of net collections) Anterior, Arintra, Commure Utilization Management & Prior Auth $30B to $45B In-house utilization review nurses, manual administrative coordinators Affirmative auto-approval engines; agentic portal submission and status arbitration Anterior, Cohere Health, Humata Health, Honey Health Clinical Trial Screening & Abstraction $25B to $40B CRO hourly billable CRA monitoring, manual site coordinator screening Real-time EHR phenotyping, automated trial matching, structured eCRF generation Tempus AI / Deep 6 AI, ConcertAI, Paradigm Health Payer Claim Adjudication & Integrity $50B to $80B Third-Party Administrators (TPAs), legacy payment integrity vendors Autonomous claims handling, policy arbitration, and reserve modeling Pace, Strala Revenue Cycle Management and Autonomous Medical Coding Healthcare revenue cycle management (RCM) represents a domestic outsourced addressable market of approximately $50 billion to $80 billion in labour spending. Medical billing and coding are governed by strict, deterministic, and highly standardised taxonomies: approximately 70,000 ICD-10-CM diagnosis codes, 87,000 ICD-10-PCS procedural codes, and thousands of American Medical Association Current Procedural Terminology (CPT) codes. Traditional medical coding requires thousands of human coders to manually review unstructured physician encounter narratives, operative reports, and discharge summaries to assign billing alphanumeric strings. This task requires high domain intelligence but minimal strategic judgment. The regulatory rules are intricate, multi layered, and carrier specific, but they remain formalised rules. Autopilot architectures in RCM ingest unstructured clinical notes via multimodal Large Language Models (LLMs), extract documented co-morbidities, verify National Correct Coding Initiative (NCCI) edits, and generate compliant, audit ready claims without human intervention. Rather than licensing this extraction tool to health information management departments for a software fee, autopilot RCM firms contract directly with health networks to take over billing workflows on a percentage of collections basis or fee per claim model. The enterprise sales motion bypasses clinical committees: the vendor replaces offshore BPO contracts or third party legacy billing services, offering lower error rates, accelerated cash collection cycles, and reduced accounts receivable days. Payer Provider Utilisation Management and Prior Authorisation Prior authorisation represents a friction-laden administrative barrier between health plans and providers, driving high operational overhead and clinical care delays. The workflow requires cross-referencing a patient’s longitudinal medical history against granular, carrier-specific clinical coverage guidelines, such as Milliman Care Guidelines (MCG) or InterQual criteria. Historically, this has required armies of intake nurses, coordinators, and BPO personnel navigating payor web portals, compiling clinical chart extracts and exchanging clinical justifications via fax. Autopilot platforms deploy specialised LLM architectures capable of ingesting clinical charts, identifying relevant conservative treatment histories, laboratory values, and diagnostic imaging reports and programmatically generating or approving authorisation packages. On the health plan side, companies like Anterior deploy clinical reasoning agents integrated into core administrative systems like HealthEdge GuidingCare. By automating medical policy review and auto approving care requests that strictly conform to evidence-based guidelines, Anterior’s platform handles millions of prior authorisations across tens of millions of covered lives, achieving over 99% accuracy while driving an 85% reduction in administrative overhead. Crucially, the platform operates as an affirmative autopilot: it auto approves compliant care within minutes or escalates ambiguous charts directly to medical directors, bypassing manual intake queues. On the provider side, platforms like Honey Health use agentic browser automation to interact directly with payor portals without requiring lengthy systems integration cycles, charging providers a flat fee of $1.50 to $2.00 per completed authorisation. This completely replaces human prior authorisation coordinators and eliminates operational bottlenecks ahead of scheduled procedures. Clinical Trial Patient Matching and Chart Abstraction In biopharmaceutical clinical development, patient identification, pre-screening, and electronic case report form (eCRF) chart abstraction represent severe structural bottlenecks. Industry data indicates that approximately 80% of clinical trials fail to meet initial enrolment timelines, with 53% requiring enrolment period extensions and over 40% of trial sites under enrolling. Pharma sponsors routinely outsource protocol feasibility and trial monitoring to Contract Research Organizations (CROs), which bill sponsors on an hourly professional services basis to dispatch clinical research associates for manual chart reviews across trial sites. Autonomous clinical research platforms disrupt this CRO dominated services model. By integrating directly with provider EHRs and clinical data repositories, systems such as Tempus AI (which acquired Deep 6 AI to deploy real-time NLP querying across more than 750 hospital sites and 30 million patient records) and ConcertAI deploy agentic architectures across protocol feasibility and cohort selection. Rather than relying on human study coordinators to cross-reference inclusion and exclusion criteria, which feature complex genomic markers, prior therapeutic lines, and strict physiological parameter windows, natural language processing models parse unstructured pathology reports and physician notes in seconds. Strategic partnerships between life sciences entities, CROs like Parexel, and platforms like Paradigm Health demonstrate the viability of shifting clinical research recruitment from manual chart abstraction to automated, real time clinical trial matching. This replaces the CRO hourly billable model with guaranteed, audit-ready patient cohorts delivered directly to sponsors. The Innovator’s Dilemma: Ambient Copilots vs. Pure Play Autopilots The first wave of artificial intelligence adoption in clinical healthcare was dominated by copilots. Systems such as Abridge, Microsoft’s Nuance DAX Copilot, Suki and Ambience Healthcare introduced ambient acoustic listening into the examination room, converting physician-patient dialogue into structured clinical documentation. These applications delivered immediate clinician satisfaction by reducing documentation burden and mitigating administrative burnout. However, from an organisational and macroeconomic perspective, clinical copilots operate under a structural ceiling dictated by their delivery model and commercial architecture. Copilots are commercialised as enterprise software products sold to hospital IT departments, priced on a per-clinician, per-month SaaS licensing model typically ranging from $300 to $1,000 per user. Consequently, they draw capital exclusively from the health system’s 3% to 5% IT budget. Because the enterprise software market in healthcare is highly constrained, copilot platforms are forced into lengthy procurement RFP cycles, competing against incumbent EHR native feature rollouts. While ambient copilots generate meaningful time savings for individual practitioners, they do not dismantle the hospital's fixed labour base. The hospital still maintains its certified professional coding staff, its billing operations, its denials management infrastructure and its clinical documentation review teams. The structural vulnerability of the copilot model lies in its product paradigm: the system produces an assistive recommendation or draft note, but relies on the human clinician to manually review, edit, approve, and electronically sign the medical record. The copilot intentionally disclaims responsibility for the final output. The human physician serves as the institutional and legal firewall, reviewing the AI's generation during evening administrative hours or between patient encounters. Under the Bek thesis, if a copilot enterprise attempts to pivot toward an autopilot, promising to deliver a finished, fully executed, audit ready clinical chart or billable encounter directly to the clearinghouse, it triggers an innovator's dilemma. The copilot company’s existing buyers (physicians and IT leaders) purchased the tool precisely because it kept the physician in sovereign control of their note without changing institutional liability structures. Transitioning to an autopilot model requires cutting the human professional out of the routine execution loop, directly challenging the workflow, compensation models and professional prerogatives of the very champions who brought the software into the enterprise. Pure-play autopilots bypass clinician seat licenses altogether. Rather than positioning software inside the examination room to assist a physician in drafting a note, an autopilot managed service contracts at the enterprise leadership level (such as the CFO or Chief Operating Officer) to take over the operational pipeline, from clinical encounter recording to code assignment, claim scrubbing and final remittance matching. The autopilot enterprise assumes full responsibility for the finished product, monetising directly as an operational service and capturing the massive labor budget line that health systems previously paid to third-party BPO contractors and internal administrative staffing. Nelson Advisors: The Industrialisation of Clinical and Administrative Labour - Deconstructing the Autopilot Playbook in Healthcare The Judgment to Intelligence Migration: A Three Phase Horizon Bek formulates knowledge work as a continuum between intelligence and judgment. Intelligence work encompasses tasks governed by rules, frameworks, and objective syntax, complex operations that nonetheless resolve to correct or incorrect outputs. Judgment work requires experience, contextual taste, risk tolerance, and qualitative instinct developed over decades of practice. Over time, as artificial intelligence systems capture domain data from continuous human oversight, the frontier shifts: today’s judgment compounds into tomorrow’s intelligence. In healthcare delivery, this operational migration progresses across three phases, transitioning from deterministic administrative processing to full clinical agency. Transformation Phase Target Operational Domain Operating & Corporate Model AI vs. Human Allocation Data Compounding & Feedback Mechanism Phase 1: Administrative Autopilot Billing, denials management, prior auth, eligibility verification, scheduling 100% Autonomous Software / AI BPO Managed Service 98% AI Execution; 2% Human Exception Handling (escalation only) Rule-matching against payer clearinghouse acceptance/denial telemetry; carrier policy updates. Phase 2: Hybrid Clinical Service Post-discharge monitoring, routine chronic triage, medication adherence, cancer screening outreach Tech-Enabled Care Entity (Friendly PC-MSO structure) 90% AI Agent Task Execution; 10% Licensed Human Oversight & Liability Signature Proprietary clinical conversation logs; physician-override and nurse-intervention telemetry. Phase 3: Autonomous Clinical Judgment Protocolised first-line care, minor acute diagnosis, algorithmic chronic disease titration, automated care navigation Licensed Autonomous Digital Clinic / AI-Native Provider Group 99% Autonomous Model Agency; Clinician operating as system supervisor Longitudinal clinical outcomes data; multi-modal biomarker responses; verified diagnostic override loops. Phase 1 represents pure intelligence execution. Operations such as coding claims, matching medical necessity guidelines, submitting prior authorisations, and auto-appealing technical denials require no subjective bedside clinical judgment. The operational rules are established by the Centers for Medicare & Medicaid Services (CMS) and commercial payer contracts. In this phase, platforms operate at near-total autonomy. Human intervention is limited to exception routing: when an edge case falls below a statistical confidence threshold, it is routed to a specialised human adjudicator, whose resolution is captured to retrain the underlying agent stack. Phase 2 transitions the autopilot from the administrative back office to routine, protocolised patient-facing interactions. In this domain, tasks include post-operative discharge check-ins, medication reconciliation, hypertension and diabetes remote monitoring, preventative screening outreach, and patient navigation. Because clinical interactions introduce professional licensure and medical malpractice requirements, software cannot act as a direct vendor to the patient without a licensed human clinician of record. The operational mechanism is therefore a tech enabled care entity. This phase is embodied by platforms such as Hippocratic AI, which has raised over $404 million at a $3.5 billion valuation from investors including General Catalyst, Andreessen Horowitz, and Avenir Growth. Hippocratic AI deploys specialised, safety-focused generative AI agents built on its Polaris constellation architecture, a collection of multi-model LLMs encompassing over 4.1 trillion parameters, where primary conversational agents are monitored in real time by specialised clinical supervisor models. These agents act as virtual nurses and care coordinators across more than 300 protocolised tasks, communicating via ultra-low-latency voice and text across 25 medical specialties. The system executes approximately 90% of routine patient interaction, data gathering, and protocol guidance, freeing human registered nurses from repetitive manual outreach. When an abnormal symptom, biophysical spike, or out-of-protocol clinical anomaly is detected, the agent escalates the patient directly to an employed human clinician. Similarly, K Health has operationalised this hybrid model at scale through commercial partnerships with health systems like Cedars-Sinai (CS Connect) and payors like Elevance Health. K Health’s chat first platform ingests longitudinal patient symptoms and medical records, generating probabilistic diagnostic and treatment pathways that human physicians evaluate and authorise in a fraction of normal encounter times. Phase 3 represents the full realisation of the convergence thesis, where today's judgment becomes tomorrow's intelligence. In this terminal clinical phase, autonomous platforms progress beyond routine communication and administrative coordination to assume direct diagnostic and therapeutic agency across standardised clinical pathways. By aggregating hundreds of millions of human verified clinical encounters, override loops and longitudinal patient health outcomes from Phase 2, the underlying models develop domain judgment that equals or exceeds average human clinical benchmarks. The technological barrier to Phase 3 is rapidly falling; however, Phase 3 encounters the industry's most formidable non-technical barriers: legal licensure, medical malpractice liability and regulatory doctrines. Systemic Bottlenecks: Corporate Law, Malpractice Tort and Outcome Verifiability The autopilot thesis translates efficiently to fintech, legal document drafting, and customer relationship management, where legal risk is bounded by contract and work product is immediately verifiable. In healthcare delivery, full stack autopilot execution encounters three systemic bottlenecks: the Corporate Practice of Medicine doctrine, the medical malpractice liability regime and the epistemological verifiability problem. The Corporate Practice of Medicine Doctrine and the Friendly PC-MSO Model In the United States, corporate law strictly separates business capital from clinical delivery. Under the Corporate Practice of Medicine (CPOM) doctrine, enforced across major jurisdictions including California, New York, and Texas, a non-physician, for profit commercial entity is legally prohibited from practicing medicine, employing licensed physicians to practice medicine, or exerting operational control over medical decision making. A pure-play software company cannot hold a state medical license, bill an insurer for professional medical services under Current Procedural Terminology Evaluation and Management codes, or directly deliver clinical diagnoses. To navigate this regulatory barrier, clinical autopilot companies must implement the Friendly PC-MSO legal architecture. Under this framework, two distinct legal entities are formed: The Professional Corporation (PC) is a dedicated legal entity 100% owned and held by a state licensed physician. The PC employs all clinical personnel, including physicians, nurse practitioners, and physician assistants and holds complete, sovereign legal authority over medical protocols, clinical judgment and patient care delivery. The Management Services Organization (MSO) is the technology-backed commercial corporation owned by founders and venture investors. The MSO owns the intellectual property, foundation models, computing infrastructure, non-clinical office facilities, and administrative workflows. The PC and the MSO enter into a comprehensive Management Services Agreement (MSA), whereby the MSO provides its AI platform, administrative engines and billing workflows to the PC in exchange for a Fair Market Value (FMV) management fee. While the PC-MSO model is standard across digital health, state regulators have enacted aggressive legislative and enforcement actions against private equity-backed and tech enabled MSOs that infringe upon clinical independence. California’s Senate Bill 351 codifies strict prohibitions barring MSOs from directly or indirectly influencing clinical judgment, setting physician diagnostic quotas, dictating clinical appointment durations, or managing clinical staff hiring and firing based on business metrics. Furthermore, high-profile enforcement actions, such as the California Attorney General’s $4.4 million settlement against Carbon Health and its leadership, demonstrate that regulatory bodies actively prosecute arrangements where an MSO exerts de facto operational control over clinical practices, patient billing communications, or provider equity transfer restrictions. For clinical autopilots, every attempt to optimise clinical throughput via autonomous algorithms risks regulatory scrutiny for unauthorised corporate practice of medicine or illegal fee-splitting. Tort Law, the Learned Intermediary Doctrine and the Malpractice Defence Software cannot carry standard medical malpractice insurance; only licensed human clinicians and accredited clinical entities can be insured against professional medical negligence. The American civil liability regime historically relies on the Learned Intermediary Doctrine in cases involving medical technology and pharmaceuticals. Under this doctrine, a medical device manufacturer satisfies its legal duty of care by providing adequate warnings, risk profiles and operational parameters to the licensed physician; the physician functions as an informed, independent intermediary who evaluates the technology and bears legal responsibility for its application to the patient. When applied to clinical AI autopilots, this legal framework produces an operational and structural paradox characterised by two distinct dynamics: The first dynamic is the negative outcome penalty paradox. If an autonomous diagnostic algorithm suggests an erroneous therapeutic regimen and the supervising clinician rubber-stamps it without independent review, courts reject the argument that the algorithm directed the treatment. The clinician is held liable for medical malpractice on the grounds of abandoning independent professional medical judgment. Conversely, if a validated, highly accurate clinical algorithm recommends a critical diagnostic intervention that the human clinician rejects or ignores, and the patient suffers harm, the clinician faces severe malpractice exposure for failing to heed standard of care algorithmic telemetry. The second dynamic is the breakdown of products liability protections. If an AI autopilot transitions to true autonomy in Phase 3 operating without human in the loop clinical mediation, the legal system loses its human learned intermediary. Legal scholars and courts increasingly advocate for subjecting substitutive, autonomous clinical AI to strict products liability up and down the deployment chain. Under strict liability, the AI company is held liable for software errors regardless of the standard of care or institutional diligence. This creates an immense financial liability profile: a pure play software vendor cannot withstand catastrophic class action malpractice or products liability exposure on a standard software gross margin, forcing the enterprise to integrate deeply into captive insurance structures, risk pools, and professional corporate vehicles. The Epistemological Verifiability Problem In white collar verticals like legal document generation or computer software engineering, the verifiability of work product is immediate. An enterprise software engineer writes a test suite; the code compiles and passes, or it fails. A commercial agreement contains mandatory corporate carve outs or it does not. In clinical healthcare, true outcome verifiability is non-deterministic, multi-factorial, and longitudinally delayed by months or years. If an AI system designs a disease management protocol for an early stage diabetic or hypertensive patient, determining whether that care management was optimal involves complex biological noise, environmental inputs, patient non compliance, and socioeconomic variables. Because ultimate clinical endpoints, such as mortality, end stage renal disease, or major cardiovascular events, take years or decades to manifest, commercial autopilot pricing cannot be tied directly to absolute clinical outcomes. Instead, tech enabled care entities are forced to construct outcome-based billing around intermediate, statistical clinical proxies. These proxies include: Glycated hemoglobin reduction thresholds in type 2 diabetes management Systolic and diastolic blood pressure control metrics within targeted patient cohorts CMS-defined 30-day all-cause hospital readmission penalties avoided First-pass clean-claim submission percentages in billing pipelines However, reliance on clinical proxies introduces severe second-order vulnerabilities. Whenever an algorithmic system is monetised against a statistical proxy, it becomes susceptible to Goodhart’s Law: when a measure becomes a target, it ceases to be a reliable measure. Autonomous clinical autopilots run the structural risk of optimising proxy markers (such as aggressive pharmacologic suppression in ways that maximise short term reimbursement metrics while failing to improve aggregate longitudinal health outcomes or lifetime medical costs. The Terminal Market State: AI Native Managed Care and Full Risk Systems The culmination of Julien Bek’s thesis suggests that the next trillion dollar market outcome will not be an infrastructure software company, an EHR database, or an AI tool suite; it will be an AI-native managed care organisation or integrated health system that replaces the human administrative and routine clinical routing apparatus with autonomous algorithmic agents, capturing the multi-trillion-dollar healthcare delivery line item directly. Global Risk Capitation as the Economic Engine In the traditional fee for service framework, hospitals bill for every incremental bed day, diagnostic test, and procedural intervention. In this volume driven environment, an AI autopilot that reduces downstream hospitalisations directly undermines the hospital's primary revenue driver. Consequently, the AI-native autopilot enterprise can only realise its full economic potential under value-based care, specifically through full-risk global capitation. Under global capitation, the AI native entity contracts with Medicare Advantage, Managed Medicaid, or commercial self-insured employers to manage a defined patient panel for a fixed Per-Member Per-Month (PMPM) or Per Member Per Year (PMPY) payment, ranging from $6,000 to over $14,000 annually for high-need geriatric populations. In this structure, the financial incentives invert: every unnecessary hospitalisation, emergency department readmission, and duplicative specialist consult represents an expense against the capitated premium. An AI-native provider that replaces expensive human nurse call centres, continuous remote monitoring triage, and routine administrative routing with autonomous software agents lowers its operational medical expense ratio, generating substantial operating margins while delivering protocolised clinical oversight. The Medical Loss Ratio Paradox and Quality Improvement Activities However, operating as an AI-native health insurer introduces a rigid statutory constraint: the Medical Loss Ratio (MLR). Established under the Affordable Care Act (ACA), the MLR requires health insurance issuers in commercial and Medicare Advantage markets to spend at least 80% to 85% of premium revenues directly on clinical medical care and clinical Quality Improvement Activities (QIA). Only 15% to 20% of premium revenues may be retained for general administrative expenses, overhead, and corporate profit. If an AI native health plan achieves hyper-efficiency by replacing administrative staff and manual utilisation management with autonomous algorithms, lowering total administrative spend to 5% of revenue, the statutory MLR calculation limits the entity's ability to simply pocket the 15% margin differential. Under federal rules, an insurer whose medical spending falls below the 80% to 85% floor must issue cash rebates to policyholders. To overcome this regulatory constraint and capture software-like gross margins, the AI-native managed care organisation relies on federal accounting rules governing Quality Improvement Activities. Federal regulations allow specific technology expenditures to be accounted for inside the clinical medical loss numerator, rather than the administrative denominator, if the technology directly supports clinical care delivery, prevents hospital readmissions, improves patient safety, or manages chronic illnesses. By embedding AI agents as patient-facing clinical care coordinators, real-time biophysical triage engines, and autonomous case managers, the AI-native health plan classifies its computational infrastructure and model operational costs as clinical care expenditures. Furthermore, by organising as a Provider-Sponsored Health Plan or an MSO holding delegated downstream risk from major payers, the enterprise absorbs clinical risk at the provider group level, where traditional carrier-level MLR constraints do not cap operating margins. Failure Modes of Automation: The Forward Health Cautionary Case The pursuit of tech native, automated healthcare delivery offers critical cautionary lessons regarding the failure modes of physical automation versus pure-play software autopilots. In late 2024, Forward Health, a venture-backed primary care company that had raised more than $650 million from prominent venture firms, including Founders Fund and Khosla Ventures, and achieved a $1 billion valuation, abruptly ceased operations, closed all physical clinic locations, disabled its consumer software, and terminated its workforce. Evaluation Parameter Forward Health Capital Intensive Model AI Native Software Autopilot Model Capital Allocation Heavy capital expenditure in urban real estate and custom hardware kiosks ($1M/CarePod) Zero physical clinic capital expenditure; cloud-native API and browser-agent architecture Reimbursement Strategy Out-of-pocket consumer membership fees ($99 to $150 per month) bypassing insurance Taps existing institutional BPO budgets, carrier fee schedules, and capitated premiums Care Delivery Interface Unattended physical kiosks executing invasive procedures (blood draws, sensor arrays) Multimodal conversational voice/text agents and automated administrative pipelines Failure Vulnerability Mechanical breakdown, field maintenance costs, hardware depreciation, patient alienation Model drift, hallucination risk, regulatory CPOM compliance, edge-case exception handling Terminal Outcome Abrupt liquidation, loss of patient records, total loss of invested venture capital Compounds operational domain data, expanding gross margins and enterprise software valuation The autopsy of Forward Health's collapse provides a case study in execution failure for the healthcare autopilot thesis. After operating tech-forward urban clinics in high-rent metropolitan markets, Forward attempted an aggressive pivot in 2023, raising a $100 million Series E round to build and deploy CarePods, unmanned, custom manufactured, AI driven physical healthcare kiosks placed in shopping malls and commercial gyms. Designed as kiosks costing roughly $1 million each to produce, the CarePods were intended to automate blood draws, biometric scans, and routine diagnostics without human medical staff on site. Physical clinical delivery resisted unattended mechanical automation. Former personnel reported that patients experienced frequent hardware malfunctions, capillary blood-draw devices failed, and technical breakdowns occurred without on-site clinical support to resolve them. By treating healthcare as a consumer hardware kiosk problem rather than an orchestration and cognitive workflow problem, Forward incurred substantial physical depreciation and maintenance costs. Simultaneously, Forward attempted to fund high fixed real estate costs, expensive custom hardware manufacturing, and an internal engineering cadre through an out-of-pocket consumer subscription fee of $99 to $150 per month, completely decoupled from commercial health insurance or Medicare reimbursement rails. The model failed to achieve the subscriber density required to service its hardware capital structure, burning through runway before proving unit-economic viability. When capital availability contracted in late 2024, Forward’s sudden shutdown resulted in patients abruptly losing access to their electronic health records, stranding patient care and triggering regulatory and clinical backlash. The Forward Health collapse underscores a fundamental boundary in the healthcare autopilot thesis: healthcare delivery cannot be solved by replacing human clinical facilities with unstaffed hardware kiosks. Physical clinical care demands human empathy, tactile examination, and an unbroken duty of care. The viable path for an AI autopilot is not the elimination of physical care infrastructure through consumer hardware, but the complete virtualisation, automation and algorithmic augmentation of the administrative, analytical, and protocolised clinical workflows operating behind licensed clinicians. Strategic Outlook and Nuanced Conclusions The application of Julien Bek’s "Services: The New Software" thesis to healthcare reveals both an expansive economic opportunity and a formidable set of regulatory, legal, and operational boundaries. Health systems operate under an inverted financial profile: administrative and clinical labor consumes the vast majority of hospital operating revenues, while enterprise software IT budgets remain firmly capped between 3% and 5%. Software vendors that persist in selling per-seat copilot applications to hospital IT departments face an innovator’s dilemma, trapped under SaaS margin ceilings and forced to keep clinicians manually executing documentation to manage institutional liability. Enterprise value in healthcare AI will accrue to pure play autopilots that capture the labor budget directly. The operational wedge begins where work is already heavily outsourced, cognitive tasks are rule-governed intelligence, and outputs are readily verifiable: autonomous medical coding, prior authorization adjudication, and clinical trial chart abstraction. In these administrative arenas, platforms displace traditional BPOs and CROs via outcome contingent pricing, expanding gross margins with every improvement in underlying algorithmic precision. As these systems compound operational data, the frontier shifts from back-office intelligence to clinical care coordination. However, scaling from an administrative autopilot to a full-stack clinical entity requires mastering the structural realities of American healthcare: First, corporate structures must strictly adhere to the Friendly PC-MSO model to comply with Corporate Practice of Medicine mandates, navigating state-level legislative actions such as California SB 351 that penalise MSO interference in clinical workflows. Second, clinical risk must be managed within the Learned Intermediary Doctrine and malpractice tort regimes, utilising human in the loop clinical supervision until legal structures can accommodate substitutive AI strict liability. Third, founders and investors must avoid the capital-intensive hardware and out-of-pocket consumer subscription traps that precipitated the collapse of Forward Health, focusing instead on software orchestration and payer-reimbursed clinical services. Finally, scalable monetisation requires operating within value-based, capitated reimbursement structures where operational labor reduction generates enterprise profitability, while legally classifying AI algorithmic care coordination as Quality Improvement Activities under statutory Medical Loss Ratio rules. The healthcare ecosystem will not be transformed by consumer hardware gadgets or incremental documentation tools. The ultimate market leader will be an AI native managed care organisation and integrated clinical delivery network, a technology enterprise operating within a compliant clinical services structure, utilising autonomous cognitive agents to eliminate administrative friction and routine clinical routing, running at software gross margins while delivering high-touch, protocolised patient care. Nelson Advisors > European HealthTech, MedTech, Digital Health Investment Banking Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, MedTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies.www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, industry trends, deal commentary, market analysis & predictions @ https://www.healthcare.digital Nelson Advisors publish Europe's Leading Healthcare Technology Investment Banking Newsletter every week, join 5000+ HealthTech and MedTech subscribers today! https://lnkd.in/e5hTp_xb Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards, corporates, venture capital and private investors to maximise shareholder value and investment returns.www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech#MedTech#DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #FemTech#ConsumerHealth #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA#Canada#Commonwealth#CorporateDivestitures #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Nelson Advisors @ 2026 Events Digital Health Rewired > March 2026 > Birmingham, UK NHS ConfedExpo > June 2026 > Manchester, UK HLTH Europe > June 2026, Amsterdam, Netherlands HIMSS AI in Healthcare > July 2026, New York, USA Bits & Pretzels > September 2026, Munich, Germany World Health Summit 2026 > October 2026, Berlin, Germany HealthInvestor Healthcare Summit > October 2026, London, UK HLTH USA 2026 > October 2026, USA Barclays Health Elevate > October 2026, London, UK Web Summit 2026 > November 2026, Lisbon, Portugal MEDICA 2026 > November 2026, Düsseldorf, Germany Venture Capital World Summit > December 2026 Toronto, Canada Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, MedTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

Nelson Advisors: Accurx Scribe, powered by Tandem - European HealthTech Case Study How a London communications platform and a Stockholm AI company built the NHS's fastest scaling ambient scribe, and what founders and investors should take from it Introduction Strategic partnerships in HealthTech are announced often and delivered rarely. The press release is easy; the shared roadmap, the aligned commercial incentives and the willingness to let another company sit between you and your customer are hard. Which is why Accurx Scribe, powered by Tandem, deserves attention as one of the more instructive European HealthTech stories of the last eighteen months. In May 2025, Accurx, the London-based communications platform used by 98% of GP practices in England and more than 200,000 NHS staff, announced that it would embed Tandem Health's ambient AI scribe into its own product rather than build one from scratch. Sixteen months later, Accurx Scribe has secured 25 Trust-wide contracts, with a significant pipeline of pilots and proofs of concept expected to convert over the coming months as NHS England's Frontline Productivity funding flows through to the frontline. In March 2026, a joint four-year programme across University Hospitals of Leicester and University Hospitals of Northamptonshire put the tool in front of 10,000 clinicians covering roughly 2.5 million outpatient appointments a year. And on 14 September 2026, Tandem closed a $100 million Series B led by EQT's Scaleup Europe Fund, taking its total funding to $160 million. This article looks at why the partnership has worked, what each side has gained, what it teaches founders and investors about partnering in regulated markets and where the risks lie as both companies push deeper into the clinical and administrative workflow of the NHS. The Partnership in Brief The division of labour is clean. Tandem provides the underlying ambient scribe: the speech capture, transcription, summarisation and document generation engine, plus the clinical safety evidence that sits behind it. Accurx provides the distribution, the identity layer, the integration with clinical record systems and the user interface that clinicians already have open on their desktop, web and mobile devices. Tandem builds the engine; Accurx builds the car, and the car is already parked in almost every GP surgery and a growing number of hospital departments in England. That distribution advantage is the heart of the story. Accurx started life in 2016 as a messaging tool for GP practices and grew, largely through product-led adoption during the pandemic, into the default communication layer between NHS staff and patients. When Accurx Scribe launched in April 2025, it did not have to win a single new login. It appeared as a feature inside a product that clinicians were already using multiple times a day, with write-back to SystmOne and EMIS records and the ability to generate referral letters, Advice and Guidance requests, appointment summaries and patient follow-up messages from the same consultation capture. Tandem, founded in Stockholm and led by CEO Lukas Saari, had been building a first party product across the Nordics and Europe. By the time of the partnership it had a growing evidence base, a clinical team of in-house doctors and a product used across thousands of care organisations. What it lacked in the UK was reach. Accurx provided reach at a scale no direct sales effort could have matched. Why It Has Worked: The Timing of the NHS Market Partnerships succeed or fail partly on their own merits and partly on the market they enter. Accurx and Tandem timed theirs well. In 2025, NHS England moved from cautious guidance on ambient voice technology to active encouragement. The MHRA clarified that most AVT products generating clinical documentation are medical devices, which raised the bar for suppliers but also legitimised the category. NHS England then published the Ambient Voice Technology Self-Certified Supplier Registry, listing 19 suppliers in January 2026 who could demonstrate Class 1 medical device registration, a current DTAC assessment, evidence of benefit in NHS settings, integration capability with existing NHS infrastructure, scalability, performance monitoring and an indicative price list. Both Accurx and Tandem are on that registry, in their own right. The registry matters because it turned a chaotic market of pilots into something Trusts could procure against with confidence. But the more important development was money. The Frontline Productivity programme, NHS England's plan to fund digital tools that release clinical time, is now beginning to flow to Trusts. Fully funded AVT pilots were opened to Trusts during 2026, and the conversion of those pilots into multi-year contracts is what will define the winners in this category over the next twelve months. Accurx Scribe was positioned ahead of that wave rather than behind it. Twenty-five Trust-wide contracts before the bulk of central funding has arrived is a strong leading indicator. When the funding lands, procurement teams tend to gravitate towards suppliers who are already live in comparable Trusts, already integrated with the relevant EPR and already on the national registry. Accurx ticks all three boxes, and its Scribe pipeline reflects that. Benefits for Accurx The most obvious benefit to Accurx is speed to market. Building a clinically safe ambient scribe from nothing is not a six-month project. It requires speech models tuned to clinical vocabulary and regional accents, a clinical safety case, medical device registration, a large evaluation effort and a team of clinicians to validate outputs. Tandem had done that work. By partnering, Accurx launched a credible product in the same quarter that the market began to move, rather than a year later. The second benefit is strategic. Accurx has always faced the question of what sits beyond messaging. A communication layer is valuable but potentially commoditised, and the company has spent years extending into triage, batch messaging, patient-initiated follow-up and, increasingly, secondary care. Ambient scribing pulls Accurx into the consultation itself, the moment where clinical value is created. Once Accurx is capturing the consultation, it is natural for it to own the documents, the letters, the coding and the follow-up communication that flow from that consultation. Scribe converts Accurx from a tool that sends messages into a platform that generates the content of those messages. That is precisely the direction the company is now taking. Accurx is extending Scribe into the end-to-end clinical and secretarial workflow: not just capturing the consultation and generating the clinical document, but managing the correspondence that follows, including sending it digitally to patients with physical letters as a fallback. In the Leicester and Northamptonshire pilot, patient letters went out the same day rather than two to three days later, and clinicians saved around eight minutes of documentation per patient and roughly an hour of administrative time per day. The third benefit is commercial. Accurx already integrates with several major Trust EPRs, a capability that many suppliers on the registry do not have. That integration, combined with Scribe, lets Accurx sell not merely a time-saving tool for clinicians but a replacement for parts of the legacy transcription, document and letter-management infrastructure that Trusts still pay significant sums for today. Outsourced medical transcription, hybrid mail contracts and document management middleware are large, unglamorous line items in Trust budgets. Displacing them is a bigger prize than a per-clinician scribe licence, and it is a prize that a pure-play scribe vendor without communication rails cannot easily reach. Benefits for Tandem For Tandem, the arithmetic is simple. The UK is one of Europe's largest healthcare markets, but selling to the NHS from Stockholm is slow, expensive and dependent on relationships that take years to build. Accurx handed Tandem a route into more than 200,000 NHS staff and, through the Trust-wide contracts now in place, tens of thousands of hospital clinicians it would have struggled to reach directly. That scale has fed back into the product. Ambient scribes improve with volume and variety of use, and the NHS gives Tandem exposure to a healthcare system with a distinctive vocabulary, a distinctive set of documents, and an unusually diverse patient and clinician population. Every consultation captured through Accurx Scribe makes Tandem's models better tuned to English-language clinical practice, an asset that carries into other markets. The partnership has also provided proof points that matter to investors. When Tandem raised its $50 million Series A in July 2025, led by Kinnevik with Northzone and Amino Collective participating, the Accurx partnership and NHS traction were central to the pitch. When it raised $100 million in September 2026 from EQT's Scaleup Europe Fund, with the same investors returning, the story had evolved: Tandem now describes itself as building an AI-native "clinic operating system" covering patient flow, triage, scheduling and patient communications across 14 European markets. The NHS, reached via Accurx, is one of the more visible reference deployments behind that ambition. Finally, the partnership has allowed Tandem to concentrate its own resources where it is strongest. Rather than building a UK sales force, integrating with SystmOne and EMIS, or navigating the NHS's information governance landscape practice by practice, Tandem could invest in model quality, clinical safety, and expansion into Germany, France, Spain and the rest of Europe. The Accurx deal is, in effect, a capital-efficient UK go-to-market that let Tandem spend its Series A on product and geographic expansion instead. An Example of a Successful Strategic Partnership What distinguishes this from the many HealthTech partnerships that go nowhere? The first factor is complementarity without overlap. Accurx had distribution and integration; Tandem had the engine. Neither was pretending to have the other's asset. Partnerships between two companies that both secretly want to own the whole stack tend to collapse into rivalry within a year. This one had a clear answer to "who does what" from the start. The second is that both parties had something meaningful at stake. Accurx put its brand on the product. "Accurx Scribe, powered by Tandem" is a co-branded proposition where Accurx carries the customer relationship and the reputational risk if the scribe makes a mistake, while Tandem's name signals the technical provenance. That mutual exposure creates discipline: neither side can treat the partnership as a side project. The third is that the partnership fits the customer's buying behaviour. NHS Trusts prefer to buy fewer things from fewer suppliers, especially where information governance, clinical safety and integration are involved. A Trust that already has an Accurx contract, an Accurx DPIA and an Accurx EPR integration can add Scribe with far less friction than it could onboard a new supplier. The partnership reduces the customer's procurement burden, which is a form of value that founders often underestimate. The fourth is speed of iteration. Because Tandem owns the model layer and Accurx owns the workflow, both can improve their part without waiting on the other. Tandem can ship better summarisation; Accurx can ship letter-management and patient communication features. The joint product improves on two tracks at once. Key Lessons for Founders The most important lesson is to be honest about which asset you actually have. Accurx could have built a scribe. Its engineering team is strong, and there was internal temptation, as there always is, to own the model. It chose not to, recognising that its scarce and defensible asset was distribution and integration, not speech to text. Founders who insist on building everything in house often lose the market to competitors who partner and ship first. Speed to market in a category that is being shaped by national policy and central funding is worth more than architectural purity. The second lesson is that distribution is a product. Tandem's decision to go through Accurx rather than around it was not a concession; it was a recognition that the UK market rewards whoever is already on the clinician's screen. European founders expanding into the NHS should ask who already owns the workflow they want to enter and whether partnering with that company is faster and cheaper than displacing them. The third lesson is to align with the regulatory and funding calendar. Both companies invested early in medical device registration, DTAC and clinical evidence, which put them on the AVT registry in the first cohort. That early compliance investment, which many startups see as overhead, turned into a moat when the registry became the procurement gateway. Founders selling into the NHS should treat regulatory readiness as a go-to-market activity, not a legal one. The fourth is to sell the outcome, not the feature. Time saved per consultation is a nice metric, but Trusts do not have a budget line called "clinician time." They do have budget lines for transcription, document management and hybrid mail. Accurx has been disciplined about framing Scribe as infrastructure replacement rather than a productivity gadget, and that framing is what unlocks Trust-wide, multi-year contracts rather than departmental pilots. The fifth lesson, and the least comfortable, is to think about what happens when the partnership succeeds. Success creates its own pressures, and both companies are now large enough that their interests will not always align perfectly. Founders should negotiate for the day the partnership works, not just the day it launches. Key Lessons for Investors For investors, the case study challenges a common assumption that partnerships signal weakness. Tandem's investors backed a company whose largest single market was reached through someone else's brand. That would make some venture investors nervous. Yet it is precisely because the partnership worked that Tandem could raise $150 million across two rounds in fourteen months while spending its capital on product and European expansion rather than a UK sales team. The question investors should ask is not "does the company own the customer?" but "does the company own something the customer relationship depends on?" Tandem owns the model, the clinical safety evidence and, increasingly, the data flywheel. Accurx owns the workflow, the integrations and the trust of NHS IT and IG teams. Both are defensible. Neither is complete alone. A second lesson is that in publicly funded health systems, the timing of central funding programmes is a leading indicator that private-market investors frequently miss. The Frontline Productivity programme, the AVT registry and the funded pilots were all visible in policy documents months before contracts appeared. Investors who track NHS England's policy calendar as closely as they track a company's ARR will price these opportunities better. A third lesson concerns category consolidation. With 19 suppliers on the registry and a handful of them, including Microsoft Dragon, Heidi, Tortus, Corti and Lyrebird, competing for the same Trusts, the category will not support that many winners. The combination of national distribution, EPR integration and a deep-pocketed model partner is a plausible profile for one of the survivors. Investors should assess whether the companies they back have a path to that profile, on their own or through partnership. Nelson Advisors: Accurx Scribe, powered by Tandem - European HealthTech Case Study Potential Problems and Risks for Both Companies No case study is complete without the uncomfortable part. The same features that make this partnership strong create risks. For Accurx, the central risk is that it does not own the model. As ambient scribing becomes a commodity, and it will, differentiation will migrate to the workflow layer, which favours Accurx. But if the quality of the underlying scribe becomes the deciding factor in a Trust procurement, Accurx is only as good as Tandem's model and Tandem's willingness to prioritise Accurx's requirements over those of its other markets and, potentially, its other channel partners. A large European company with $160 million in funding and a stated ambition to be a "clinic operating system" will not indefinitely be content to be the engine inside someone else's brand in Europe's most valuable single-payer market. For Tandem, the mirror-image risk is that it does not own the UK customer. Accurx carries the relationship, the contract and the data flows in most Trust deployments. If Accurx were to develop or acquire its own model, or to add a second scribe provider to its platform to reduce dependency, Tandem's UK revenue could contract quickly. Tandem also faces reputational exposure it does not fully control: a clinical safety incident in an Accurx deployment would attach to Tandem's name regardless of whether the root cause lay in the model, the integration or the workflow. Both companies face the risk of a well funded incumbent. Microsoft Dragon Copilot is on the registry and is being deployed at scale in Manchester and elsewhere, bundled with the Microsoft 365 estate that every Trust already owns. Epic, Oracle Health and other EPR vendors are building native ambient documentation into their platforms. In the long run, Trusts may prefer an EPR-native scribe to a third-party one, however good the third party's integration. The Accurx-Tandem proposition depends on staying enough ahead on workflow and evidence to justify a separate contract. There is also policy risk. Central funding programmes are generous when they start and unreliable when they end. If Frontline Productivity money is slower or smaller than expected, or if it is diverted to other priorities, the pipeline of pilots that both companies are counting on could stall. Trusts that have used central funding for a two-year pilot may struggle to find recurring money when that funding expires, which is the classic NHS "pilotitis" problem. And there is regulatory risk. The MHRA's clarification that most AVT products are medical devices was helpful in defining the category, but regulators tend to raise requirements as usage grows. A shift from Class I to Class IIa classification for products that generate clinical recommendations, or tighter rules on data residency and model training, could impose costs that a smaller supplier finds harder to bear than a Microsoft. Potential Issues on the Critical Path Beyond the strategic risks are the practical bottlenecks that will determine whether 25 Trust wide contracts become 75. The first is EPR integration depth. Accurx's existing integrations with major Trust EPRs are a genuine advantage, but ambient scribing places new demands on those integrations. Writing a structured clinic letter, populating coded fields and routing correspondence to secretarial teams requires deeper write-back than sending a text message. Every EPR has different APIs, different governance and different appetite for third-party write access. Each new integration is a multi-month project, and Trusts will not convert pilots to contracts if the integration is shallow. The second is the secretarial workflow. Replacing legacy transcription and letter-management infrastructure is a bigger prize than clinician time-saving, but it is also a more complex change. Medical secretaries, clinic coordinators and outsourced transcription providers all have a stake in the current process. Trusts will need change-management support, redesigned processes and clear governance for who signs off letters generated by AI. Accurx is taking on a services-heavy transformation, not just a software rollout. The third is clinical safety at scale. Scribe outputs are reviewed by clinicians before they are filed, but as usage grows, review fatigue becomes a real issue. A model error that slips through review in one of 2.5 million outpatient appointments a year is statistically inevitable. Both companies need robust monitoring, incident reporting and a shared clinical safety framework that stands up to scrutiny from Trust clinical safety officers and, potentially, coroners. The fourth is commercial model. Trust-wide contracts on a per-clinician basis are simple to buy but expose the supplier to underutilisation. If Trusts pay for 5,000 licences and 2,000 clinicians actually use the tool, renewal conversations become difficult. Accurx and Tandem will need to demonstrate adoption, not just contract signature, and share the revenue in a way that keeps Tandem invested in UK success. The fifth is capacity. Both companies are scaling quickly. Accurx is moving from primary care, where it is dominant, into secondary care, where its position is newer. Tandem is expanding into 14 markets simultaneously. The risk that the UK partnership becomes a lower priority for one side while the other is counting on it is real, and it is the kind of misalignment that surfaces only when things are going well enough for both companies to have other options. Platform Dependency The deepest question the case study raises is one of platform dependency, in both directions. Tandem is dependent on Accurx as a channel in the UK. Accurx is dependent on Tandem as a technology supplier. Both are dependent on NHS England for the regulatory framework, the registry and the funding that is driving adoption. And both are dependent on EPR vendors for the integrations that make the product useful. Mutual dependency is not inherently unstable. It is the basis of most successful supply relationships. But it requires contractual and commercial structures that survive the moment when one party's alternatives improve. Investors and founders looking at this partnership should ask a set of questions to which outsiders do not have the answers. How long is the exclusivity, if any, in either direction? Who owns the data generated by NHS consultations, and can it be used to train models that Tandem deploys in other markets or through other channels? What happens to a Trust-wide contract if the partnership ends? Does Accurx have a contractual right to a second model provider, and does Tandem have a right to sell directly into the NHS in competition with its own partner? The most likely long-term evolution is one of two paths. Either the partnership deepens into something closer to a joint venture, with shared roadmaps, shared economics and possibly cross-shareholdings, or one party acquires the capability of the other. Accurx could build or buy a model; Tandem could build or buy UK distribution. Neither path is bad for the NHS, which will get a better product either way, but both paths carry execution risk and, in the acquisition case, the risk that value is transferred rather than created. There is also a broader platform dependency worth naming. Both companies sit on top of foundation models supplied by a small number of large AI labs, and both compete, directly or indirectly, with the hyperscaler that also supplies infrastructure to most NHS Trusts. That is a dependency every ambient scribe company shares, and it is the one least within any founder's control. Conclusion Accurx Scribe, powered by Tandem, is a rare example of a European HealthTech partnership that has delivered measurable scale rather than a press release. In sixteen months it has produced 25 Trust-wide contracts, a 10,000-clinician multi-Trust programme, a place on the national registry for both companies and a significant contribution to Tandem's $160 million of funding. It has done so because the two companies brought complementary assets, aligned with the NHS's regulatory and funding calendar, and were disciplined about selling infrastructure replacement rather than a feature. The lessons for founders are to be honest about which asset you own, to treat distribution and regulatory readiness as products, and to negotiate for the day the partnership succeeds. The lessons for investors are to look past who owns the customer to who owns what the customer relationship depends on, and to read the policy calendar as carefully as the metrics. The risks are real. Neither company owns the whole stack. Both face incumbents with deeper pockets and EPR vendors with more natural integration. Central funding is generous now and uncertain later. And the mutual dependency that makes the partnership work today is the same dependency that could strain it tomorrow. For now, though, this is what a successful strategic partnership in European HealthTech looks like: two companies, each doing what it does best, in a market that finally has the policy, the funding and the appetite to reward them for it. The next twelve months, as the pilot pipeline converts and Frontline Productivity funding lands, will show whether the model holds. Nelson Advisors > European HealthTech, MedTech, Digital Health Investment Banking Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, MedTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies.www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, industry trends, deal commentary, market analysis & predictions @ https://www.healthcare.digital Nelson Advisors publish Europe's Leading Healthcare Technology Investment Banking Newsletter every week, join 5000+ HealthTech and MedTech subscribers today! https://lnkd.in/e5hTp_xb Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards, corporates, venture capital and private investors to maximise shareholder value and investment returns.www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech#MedTech#DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #FemTech#ConsumerHealth #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA#Canada#Commonwealth#CorporateDivestitures #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Nelson Advisors @ 2026 Events Digital Health Rewired > March 2026 > Birmingham, UK NHS ConfedExpo > June 2026 > Manchester, UK HLTH Europe > June 2026, Amsterdam, Netherlands HIMSS AI in Healthcare > July 2026, New York, USA Bits & Pretzels > September 2026, Munich, Germany World Health Summit 2026 > October 2026, Berlin, Germany HealthInvestor Healthcare Summit > October 2026, London, UK HLTH USA 2026 > October 2026, USA Barclays Health Elevate > October 2026, London, UK Web Summit 2026 > November 2026, Lisbon, Portugal MEDICA 2026 > November 2026, Düsseldorf, Germany Venture Capital World Summit > December 2026 Toronto, Canada Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, MedTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies.www.nelsonadvisors.co.uk

10 Key Points from Morgan Stanley’s 24th Annual Global Healthcare Conference Morgan Stanley's 24th Annual Global Healthcare Conference ran in New York from Monday 14 to roughly Wednesday 16 September 2026, drawing around 3,000 investors and executives across biopharma, biotech, medtech and health services. Company sessions were the usual fireside-chat format with live webcasts: Merck's CEO Robert Davis and R&D head Dean Li spoke on the Monday, and Tuesday featured Amgen (Jay Bradner and CFO Thomas Dittrich), AbbVie, STERIS, Sight Sciences and others, with J&J, GRAIL, Schrödinger, Cytokinetics, Vir, Eikon and BrightSpring also on the roster. Morgan Stanley's own published wrap-up (16 September) framed three headline themes: new innovation around Alzheimer's, the expanding reach of GLP-1 therapies beyond their original indications, and AI's capacity to accelerate drug development and cut costs, with the bank putting potential healthcare savings from AI at $300–900 billion by 2050. Featured voices included John Collins, Morgan Stanley's global head of M&A, on deal trends, Wellhub CEO Cesar Carvalho on corporate wellness, and BeOne Medicines co-founder John Oyler on cancer treatment access and trial innovation. From the company sessions, AbbVie was a notable one: it said it has offset $18bn of Humira erosion with $28bn of growth from other platforms, flagged its Apogee acquisition as its most significant deal since Allergan, and confirmed its entry into obesity via the amylin asset from Gubra. Transcripts for a long list of other presenters (Sarepta, Dyne, Zentalis, Getinge, ORIC, Inventiva and more) are available on Seeking Alpha and Investing.com. Core Themes & Highlights Market Rebound & M&A Momentum: Investor sentiment rebounded from previous headwinds, supported by resilient procedure volumes, stronger healthcare utilisation, and a clearer macroeconomic backdrop encouraging capital deployment and strategic dealmaking. Emerging Biotech & Novel Platforms: Presentations heavily emphasized next-generation modalities, including targeted protein degradation, AI-accelerated drug discovery, in vivo gene editing, and new therapeutic candidates for neurodegenerative diseases. Global Innovation Dynamics: Discussions highlighted the expanding role of cross-border partnerships and China's growing footprint as a high-speed, cost-efficient engine for biopharma innovation and clinical development. The Next Wave of Metabolic Treatments: While first-generation GLP-1 injectables have seen widespread adoption, executive sessions focused on next-generation oral formulations, long-term supply chain scale-up, and broader payer/Medicare coverage frameworks. Regulatory & Policy Landscape: Panels examined stabilising U.S. drug-pricing dynamics, accelerated approval mechanisms designed to maintain competitive parity in biopharma, and CMS oversight shifting toward clinical outcomes and risk-adjustment data integrity. 10 Key Points from Morgan Stanley’s 24th Annual Global Healthcare Conference Rebounding Investor Confidence: After a cautious 2025, healthcare investment and dealmaking are picking up, supported by strong healthcare utilisation rates and clearer macro conditions. Easing U.S. Policy Uncertainty: Executives reported a more predictable domestic policy environment, as key concerns surrounding tariffs, vaccine guidance, international drug pricing, and affordability have largely stabilised. China as an Innovation Powerhouse: Biopharma and biotech innovation has become a Chinese national priority, presenting opportunities for global cross-border partnerships while increasing competitive pressure due to China's faster, lower-cost drug development cycles. Faster Regulatory Approvals: U.S. regulators are expected to expedite drug approval pathways, in part to maintain competitive parity with the accelerating pace of drug development in China. CMS Dual Focus on Stability and Lower Prices: Leadership from the Centers for Medicare & Medicaid Services (CMS) emphasised a policy agenda centred on lowering out-of-pocket costs for patients while preserving industry stability and transparency. Shift Away from Coding Intensity: CMS is pushing managed care programs toward measurable health outcomes and data accuracy, aiming to curb aggressive risk-adjustment coding practices that artificially inflate federal spending. Untapped GLP-1 Growth Potential: Despite rapid adoption across diabetes and obesity indications, biopharma leaders noted that overall GLP-1 market penetration remains low relative to its addressable population. Oral GLP-1s Expand the Market: The emergence of oral GLP-1 formulations is expanding total patient reach rather than cannibalising existing injectable therapies. Expanded Medicare Access for Weight-Loss Drugs: Medicare's pilot program offering specific weight-loss therapies to Part D beneficiaries for a flat $50 monthly fee enrolled 6,000 patients within 60 days, signaling broader long-term access. Operational and R&D Efficiencies via AI: Artificial intelligence is increasingly deployed to shorten clinical development cycles, improve drug discovery screening, and streamline commercial and hospital administration workflows. Source: https://www.morganstanley.com/insights/articles/healthcare-industry-trends-global-healthcare-conference-2026

Nelson Advisors: MedTech M&A Increases 150% YOY as Private Equity Invests More Money into MedTech MedTech M&A Increases 150% YOY as Private Equity Invests More Money into MedTech, But Focuses on Deals with Bigger Tickets in Faster Growing Categories Fewer, larger, more selective: what the first half of 2026 tells us about where private capital is going in MedTech, and how investors should think about carve-outs, take-privates and the categories that are attracting the biggest cheques A Market That Got Bigger Without Getting Busier The headline number for MedTech M&A in 2026 is striking. In the first half of the year, deal value was roughly 160% higher than the same period in 2025. The more interesting number sits beside it: deal count rose by just 5%. Average deal value more than doubled, from slightly less than $1 billion to approximately $2.1 billion, according to EY and Capital IQ data. That combination, a modest increase in the number of transactions alongside a dramatic rise in value, tells you almost everything you need to know about the state of the market. This is not a broad-based recovery in which every asset finds a buyer. It is a concentration of capital into a smaller set of larger, higher-conviction transactions. Investors are paying up for the businesses they want and walking past the ones they do not. It follows a record year. PwC tracked $97.6 billion of MedTech deal value in 2025, a decade high, driven by Abbott's $21 billion acquisition of Exact Sciences, BD's $17.5 billion combination with Waters, and the $18.3 billion take-private of Hologic by Blackstone and TPG. The first half of 2026 has kept that momentum, with $36.5 billion tracked through June and five transactions above $1 billion, including Danaher's $9.9 billion acquisition of Masimo and Boston Scientific's move for Penumbra. Two things are happening at once. Large strategic MedTech companies are reshaping their portfolios towards the categories they believe will grow fastest over the next decade. And private equity, with record dry powder and a willingness to take on scale, has become the natural counterparty for the assets that strategics no longer want and the public companies that the market no longer rewards. What the Numbers Say About Selectivity The gap between value growth and volume growth is the signature of a selective market. When capital is abundant but conviction is scarce, buyers cluster around the same handful of assets and compete on price. When capital is scarce, volume falls and value falls with it. The first half of 2026 is the former: capital is available, but it is being deployed with a narrow aperture. Investors are focused on finding innovative businesses with strong growth prospects and recurring revenue models. In practice this means several things. Buyers want companies that are already commercial, or at least late-clinical with a clear path to reimbursement, rather than early-stage technology bets. They want revenue that recurs through consumables, service contracts, software subscriptions or procedure volume, rather than lumpy capital equipment sales. And they want exposure to categories where procedure growth is structurally above the market average. Those categories are well understood. Cardiovascular care, and especially structural heart, electrophysiology and peripheral vascular intervention, continues to be the centre of gravity for strategic acquirers. Boston Scientific, Medtronic, Abbott and J&J MedTech have all been active in cardiology adjacencies, with Medtronic's acquisitions of CathWorks, Scientia Vascular and SPR Therapeutics illustrating the pattern of buying late-clinical and early-commercial assets in high-growth niches. Neurostimulation and neuromodulation, connected care and remote monitoring, robotic and enabling technologies, and diagnostics with recurring consumable revenue are the other recurring themes. The corollary is that assets outside those categories, however profitable, are finding it harder to command strategic attention. That is where private equity comes in. Why Private Equity Is Moving In Three conditions have combined to make MedTech unusually attractive to financial sponsors in 2026. The first is valuation. Through the first half of 2026, MedTech equities have been trading at a discount to the S&P 500. For a sector that traded at a consistent premium for most of the last decade, that discount is a signal to buyers that public markets are underpricing durable, cash-generative businesses. Private ownership, as PwC noted in its mid-year outlook, may better support multi-year value creation for companies whose investment needs do not fit a quarterly earnings cycle. The second is dry powder. Healthcare-focused and generalist sponsors have raised very large funds over the last three years and face pressure to deploy. MedTech offers what few other healthcare subsectors can: regulated, defensible products, predictable procedure-driven demand, and, in many cases, margins that improve with scale. The third is supply. Strategic MedTech companies are increasingly focused on reducing portfolio complexity and are allocating resources to faster-growing areas or a subset of their overall portfolio. That creates a steady flow of divisions and product lines that perform well but no longer fit the growth profile or long-term strategy of a publicly traded parent. It also creates a set of standalone public companies, often themselves the product of earlier spin-offs, that lack the scale or growth to attract a strategic premium and whose boards are open to a sponsor-led exit. The recent transactions demonstrate the scale of sponsor interest. Blackstone and TPG's $18.3 billion take-private of Hologic, completed earlier this year, was the largest MedTech buyout in recent memory. American Industrial Partners agreed in April to acquire Avanos Medical for approximately $1.27 billion and closed the deal in July. KKR's approximately $5.7 billion acquisition of Integer, announced in August at $127 per share and a premium of more than 50% to the pre-review price, highlights the breadth of private capital moving into the MedTech ecosystem, including medical device contract manufacturing and refurbishing. Integer supplies electrophysiology catheters, cardiac leads and batteries to Abbott, Boston Scientific and Medtronic. Owning the manufacturer behind the fastest-growing categories is one way to get exposure to those categories without paying strategic multiples for the branded products themselves. Two Transaction Strategies Are Emerging Within that broad picture, two transaction types dominate sponsor activity: carve-outs and divestitures on one side, and take-privates on the other. They are different in structure, risk and value-creation logic, and a disciplined investor should understand both. Carve outs and divestitures What it looks like in practice. A sponsor acquires a MedTech division or product line rather than the whole company. The seller is typically a large, publicly traded strategic looking to simplify; the asset is often profitable, established and under-invested. Why strategics are selling. With MedTech equities trading at a discount to the broader market, management teams are under pressure to demonstrate that every part of the portfolio contributes to growth and margin. Divisions that are stable but slow, or that require capital the parent would rather deploy in cardiology or neuroscience, become candidates for divestiture. Selling those units lets the parent improve its blended growth rate, redeploy capital into higher-return areas and present a cleaner story to investors. The GN Store hearing business sold to Amplifon and Agilent's acquisition of Biocare Medical for $950 million are examples of assets changing hands as parents refocus. Why it appeals to PE firms. Carve outs can provide established products, customers, regulatory clearances and market share without purchasing an entire company. Crucially, the value-creation thesis does not have to rest on cost-cutting. A carved out business that was starved of investment inside a large parent can often grow through new product development, geographic expansion, commercial investment or add on acquisitions. In many instances a carve out can serve as a platform: it delivers sufficient assets, operational capabilities and financial scale to enter an attractive segment, and the sponsor then builds around it through bolt-ons. What can go wrong. Carve outs are operationally the hardest transactions in MedTech. The acquired business usually depends on the parent for quality systems, regulatory affairs, IT, distribution and shared manufacturing. Transition services agreements can be long and expensive. Regulatory clearances and CE marks may be held in the parent's name and need to be transferred, a process that varies by jurisdiction and can take months. Customer contracts may be bundled with products the buyer is not acquiring. Sponsors that underestimate the standalone cost base or the timeline to full separation routinely see the first two years of their plan consumed by disentanglement rather than growth. Take privates What it looks like in practice. A sponsor, or a consortium, acquires a listed MedTech company in its entirety, typically at a premium to the undisturbed share price, and delists it. Why boards are selling. Public MedTech companies below a certain scale face a structural problem. They are too small to attract the analyst coverage and index inclusion that support a full valuation, but too large to be acquired by most strategics without a premium those strategics are unwilling to pay for slower-growth assets. Boards of such companies, when approached by a sponsor offering a 40% to 50% premium, have a fiduciary reason to engage. Hologic, Avanos and Integer all fit that profile in different ways: durable businesses, credible management, and a public valuation that did not reflect what a patient owner could build. Why it appeals to PE firms. Take-privates deliver a complete business with its own infrastructure, so the separation risk of a carve-out is absent. The value-creation thesis usually rests on capital allocation freed from quarterly scrutiny: investing in capacity, product pipelines or M&A that the public market would have punished in the short term. Integer's own explanation of the KKR deal, that private ownership would provide "flexibility and long-term capital to invest in its capacity, technology and innovation," captures the logic precisely. What can go wrong. Take-privates are expensive. The premium is paid up front, the leverage is real, and the exit depends on either a strategic buyer emerging in three to five years or an IPO market that is receptive. A business that was slow-growing in public hands does not become fast-growing simply by delisting. Sponsors need a concrete plan to change the growth trajectory, whether through product, geography or acquisition, and that plan has to survive tariff uncertainty, supply chain disruption and rate movements, all of which PwC identifies as headwinds shaping dealmaker behaviour in 2026. The Categories Attracting the Biggest Tickets The shift to bigger tickets is not random. It reflects where both strategics and sponsors believe structural growth lies. Cardiovascular remains the largest and most contested category. Structural heart, driven by transcatheter valve replacement and repair, continues to expand its addressable population as indications broaden. Electrophysiology has been transformed by pulsed field ablation, and every major player is investing to defend or capture share. Peripheral vascular, including thrombectomy and coronary imaging, is where Boston Scientific's Penumbra deal and Medtronic's smaller acquisitions sit. For sponsors, the way into cardiology is often indirect: through contract manufacturers like Integer, through component suppliers, or through service and refurbishment businesses that ride procedure volume without competing with the strategics. Neurostimulation and neuromodulation are the second theme. Spinal cord stimulation, deep brain stimulation, peripheral nerve stimulation and a growing set of indications in pain, movement disorders and psychiatric conditions are attracting both strategic and sponsor capital. The recurring revenue profile, with implantable generators and follow-on replacements, suits the models that investors favour. Connected care and remote monitoring form the third. Devices that generate data, software that interprets it and services that act on it have moved from pilot to reimbursement in several major markets, and the recurring revenue and switching costs of connected platforms are attractive to sponsors who have seen the same dynamics in software. Diagnostics with consumable pull-through, surgical robotics and enabling technology, and specialty categories such as women's health, where Hologic sits, round out the list. In each case, the common thread is a combination of procedure growth above the market, a recurring revenue mechanism, and a regulatory moat that a well-capitalised owner can widen. What is notable is what is absent. Commoditised consumables, capital equipment with long replacement cycles and categories exposed to reimbursement pressure or tariffs are not where the big tickets are going. Those assets still transact, but at multiples and in structures that reflect their profile. Nelson Advisors: MedTech M&A Increases 150% YOY as Private Equity Invests More Money into MedTech A Disciplined Targeting Framework MedTech deal opportunities are plentiful, but finding the right ones and capitalising on them requires a disciplined targeting framework and an in-depth understanding of operational, regulatory and execution risk. For a sponsor or a strategic evaluating the current market, that framework needs to address at least five questions. The first is category conviction. Does the asset sit in a segment where procedure volume, reimbursement and clinical evidence are moving in the right direction over a five-year horizon? Buying a well-run business in a shrinking category is a value trap, and the market's shift to fewer, larger deals is a rational response to that risk. The second is the source of growth. If the thesis depends on growth rather than cost, where specifically will it come from? New indications, new geographies, a pipeline product, a commercial investment the parent never made, or bolt-on acquisitions? Each of those has a different risk profile and a different timeline, and a plan that relies on all of them at once is not a plan. The third is regulatory and quality posture. MedTech is a regulated industry, and the quality of a target's quality system is often the single largest determinant of post-deal surprises. An FDA warning letter, an EU MDR transition that has not been completed, or a quality management system that lives inside a parent's infrastructure and will need to be rebuilt can each consume a year of the value-creation plan. Due diligence that treats regulatory affairs as a box to tick rather than a core workstream is where carve-outs go wrong. The fourth is operational separability, which applies to carve-outs specifically but also to take-privates of companies with entangled supply chains. What does the business actually cost to run on a standalone basis, and how long will it take to get there? Sponsors that have done multiple carve-outs tend to have a realistic view; those doing their first tend to be optimistic. The fifth is exit. Who buys this business in five years, and at what multiple? If the answer is a strategic, does the asset fit the categories strategics are buying? If the answer is another sponsor, is the growth story credible enough to support a secondary buyout at a higher price? If the answer is an IPO, is the business large and growing enough to command public attention that the current owner lacked? The market's own behaviour, in which strategics pay up for high-growth categories and let the rest go, is the best guide to what exits will look like. Implications for Strategics, Sponsors and Founders For large strategic MedTech companies, the current market is an opportunity to reshape portfolios on favourable terms. Sponsors are willing to pay reasonable prices for non-core assets, and the capital released can be redeployed into the categories where strategics have the strongest right to win. The risk is that the divested businesses, freed from the parent's constraints and given investment, become competitors or acquisition targets for rivals. For private equity, the opportunity is obvious but the discipline required is considerable. The businesses available are, by definition, the ones strategics have decided not to prioritise. That does not make them bad businesses, but it does mean the sponsor's value-creation thesis has to be more specific than "we will run it better." The most successful MedTech sponsors have built operating capabilities in regulatory affairs, quality, commercial execution and add-on integration, and treat those capabilities as part of the investment case rather than a service they buy in after closing. For founders and management teams of growth stage MedTech companies, the message is that capital is available for businesses that fit the profile: commercial traction, recurring revenue, a defensible regulatory position and exposure to a category with structural tailwinds. Companies that do not fit that profile will find fundraising and exit harder than the headline M&A numbers suggest. The market is rewarding scale and clarity, not breadth. Risks to the Thesis The first half of 2026 has been strong, but several things could change the picture in the second half and into 2027. Financing conditions matter more for take-privates than for any other transaction type. A sustained move in credit spreads or rates would change the arithmetic on large leveraged deals quickly. The Hologic and Integer transactions were financed in a window that may not persist. Tariffs and supply chain disruption, which PwC flagged as shifting dealmaker focus towards operational resilience, affect MedTech disproportionately because of its globalised manufacturing footprint. A carve-out with manufacturing in tariff-exposed jurisdictions carries risk that did not exist two years ago. Regulatory change, whether in the form of EU MDR enforcement, FDA policy on software and AI-enabled devices, or reimbursement decisions in the categories attracting the most capital, could shift the growth profile of individual segments quickly. And there is the risk of crowding. When every sponsor is targeting the same categories and the same transaction types, prices rise and returns compress. The average deal value more than doubling in a year is a sign of conviction, but it is also a sign that buyers are competing for a limited set of assets. The discipline that the market currently displays in volume may not survive a further increase in the capital chasing it. Conclusion MedTech M&A in 2026 is bigger, more concentrated and more selective than it was a year ago. Value is up roughly 160% year on year on a deal count that has barely moved, and the average ticket has more than doubled. That reflects two forces acting together: strategics repositioning towards cardiovascular, neuro-stimulation and connected care, and private equity stepping in, at scale, to buy the assets that strategics no longer prioritise and the public companies that markets no longer reward. Carve outs and take privates are the two strategies through which that capital is flowing, and each carries a distinct set of risks. Carve outs offer growth without separation risk only for buyers who understand what separation actually costs. Take privates offer complete businesses only for buyers who can articulate what changes under private ownership. The opportunity set is large. But the market's own behaviour, its preference for fewer, larger, higher-quality transactions, is the clearest possible guidance for anyone entering it. In this environment, the winners will be the investors with a disciplined framework for choosing targets and a clear-eyed understanding of the operational, regulatory and execution risks that sit behind every deal. Nelson Advisors > European HealthTech, MedTech, Digital Health Investment Banking Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, MedTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, industry trends, deal commentary, market analysis & predictions @ https://www.healthcare.digital Nelson Advisors publish Europe's Leading Healthcare Technology Investment Banking Newsletter every week, join 5000+ HealthTech and MedTech subscribers today! https://lnkd.in/e5hTp_xb Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards, corporates, venture capital and private investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech#MedTech#DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #FemTech#ConsumerHealth #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA#Canada#Commonwealth#CorporateDivestitures #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Nelson Advisors @ 2026 Events Digital Health Rewired > March 2026 > Birmingham, UK NHS ConfedExpo > June 2026 > Manchester, UK HLTH Europe > June 2026, Amsterdam, Netherlands HIMSS AI in Healthcare > July 2026, New York, USA Bits & Pretzels > September 2026, Munich, Germany World Health Summit 2026 > October 2026, Berlin, Germany HealthInvestor Healthcare Summit > October 2026, London, UK HLTH USA 2026 > October 2026, USA Barclays Health Elevate > October 2026, London, UK Web Summit 2026 > November 2026, Lisbon, Portugal MEDICA 2026 > November 2026, Düsseldorf, Germany Venture Capital World Summit > December 2026 Toronto, Canada Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, MedTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

Nelson Advisors: This Week in European HealthTech, MedTech and Health AI: 18th September 2026 European HealthTech continues to see heavy capital flow toward clinical workflow automation, platform consolidation and regulatory alignment under evolving EU frameworks. Late Stage Rounds & Clinical Automation Tandem Health (Sweden) raised $100M in Series B funding, backed by the EU's €5B tech startup initiative, to scale its clinical workflow and administrative AI platform across European healthcare networks. Holifya (Italy) closed a €2M round to expand its AI-assisted digital clinic model targeting metabolic health and GLP-1 therapy adherence, demonstrating continued niche appetite for integrated virtual clinic platforms. Venture capital continues shifting decisively away from standalone consumer wellness apps, heavily prioritising deep-tech diagnostics, trial infrastructure, and "clinical plumbing" (such as Qureight and Ahead Health). M&A, Platform Building & Cross Border Expansion Hygie31 acquired a majority stake in Ireland's Navi Group, expanding the French pharmacy and healthcare platform into English-speaking Europe to consolidate fragmented dispensing and care services. HCML acquired Corazon Health (UK), continuing its buy-and-build strategy to construct a centralised, tech-enabled occupational health and rehabilitation network. AddLife (Sweden) acquired Unicam Sistemas Analíticos (Portugal), expanding its distribution footprint in high-throughput laboratory tech and automated diagnostics. Investors in Healthcare Policy & Implementation Shifts NHS Ambient Voice Technology (AVT): UK trust rollouts are picking up pace under the national digital health modernisation initiative, favouring vendors with direct electronic health record (EHR) integration. EU AI Act & Medical Software: Health systems are adjusting compliance pipelines following recent Digital Omnibus adjustments. While patient-facing interactive bots face strict transparency disclosures, embedded diagnostic and SaMD (Software as a Medical Device) models are harmonizing with the MDR roadmap, deferring duplicate conformity burdens toward 2027/2028. Nelson Advisors Policy & Procurement Reform EU Public Procurement Overhaul: The European Commission introduced its proposal for a new Public Procurement Regulation, establishing the "best price-quality ratio" as the default standard to phase out lowest-price purchasing. Trade body MedTech Europe responded, advocating for a quality weighting higher than the proposed 30% minimum and warning against strict "Made in Europe" component-origin preferences that could disrupt multinational supply chains. MDR/IVDR Digitisation & Streamlining: The European Commission and notified body association Team-NB advanced a €4M project to digitise MDR and IVDR conformity assessment procedures. Additionally, the Commission expanded its Well-Established Technologies (WET) list across roughly 55 legacy medical device categories to reduce redundant certification backlogs. Digital Omnibus Clarifications: Regulatory guidance confirmed that high-risk software-as-a-medical-device (SaMD) subject to both the EU AI Act and MDR/IVDR conformity assessments will follow deferred assessment milestones toward late 2027 to prevent duplication and notified body bottlenecks. Clinical Clearances & Commercial Milestones FemPulse Ring CE Mark: Bioelectronic developer FemPulse secured CE Mark clearance under the EU MDR for its non-invasive neuro-modulation ring targeting overactive bladder, opening distribution across EU member states. Joint Clinical Assessments (JCA): National authorities and notified bodies initiated preliminary workflows for the first wave of medical devices navigating the centralised EU-wide Health Technology Assessment (HTA) framework. Venture Funding & Hardware Innovation Xeltis (€20.5M): The Dutch clinical-stage MedTech firm secured funding to accelerate clinical development of its bio-absorbable, restorative cardiovascular implants and vascular access grafts. Onalabs (€9.3M Series A): Spanish biometric hardware developer Onalabs raised capital to expand its medical-grade, non-invasive continuous sweat-monitoring wearable for clinical and remote patient monitoring. Strolll (€5M): UK-based neuro-rehabilitation provider closed combined equity and grant funding to expand hospital deployment of its augmented-reality and computer-vision physical therapy systems. Funding & Commercial Deployments Tandem Health ($100M Series B): Swedish clinical AI assistant Tandem Health secured $100 million led by the Scaleup Europe Fund (managed by EQT). The capital is earmarked to evolve its ambient scribe from consultation documentation into an autonomous, AI-native clinic operating system managing triage and patient flows across 14 European countries. Penelope Health (€87M): London-based Penelope Health raised €87 million alongside an infrastructure integration with Thoreau to automate payer rules, claims processing, and clinical revenue-cycle intelligence across European provider networks. Big Picture Bio (€2.55M): London-based computational biology startup Big Picture Bio emerged from stealth to deploy foundation models for designing synergistic multi-target cancer drug combinations. Adoption & Market Benchmarks AWS European Healthcare AI Adoption Index: A pan-European industry study released this week showed that while healthcare adoption lags the cross-industry average (41% vs. 54%), healthcare adopters report disproportionately higher returns, with 60% noting revenue expansion and 55% citing significant productivity gains. However, 54% cited an acute workforce digital skills shortage as the primary impediment to scaling. Governance & Regulatory Action EU Neuro-AI Infrastructure Framework: The European Group on Ethics in Science and New Technologies (EGE) published formal recommendations urging the European Commission to shift neuro-AI regulation from standalone device privacy to an infrastructure-level model. The proposal focuses on protecting sovereign neuro-data pools, governing synthetic neural inferences, and establishing public-interest standards for Brain Foundation Models. MDR / AI Act Harmonisation Readiness: With initial AI Act transparency rules for conversational and synthetic systems now in effect, hospital procurement teams and notified bodies have begun auditing generative clinical assistants. High-risk clinical diagnostic models continue updating single-file technical documentation ahead of the streamlined MDR integration timelines. Nelson Advisors > European HealthTech, MedTech, Digital Health Investment Banking Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, MedTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies.www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, industry trends, deal commentary, market analysis & predictions @ https://www.healthcare.digital Nelson Advisors publish Europe's Leading Healthcare Technology Investment Banking Newsletter every week, join 5000+ HealthTech and MedTech subscribers today! https://lnkd.in/e5hTp_xb Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards, corporates, venture capital and private investors to maximise shareholder value and investment returns.www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech#MedTech#DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #FemTech#ConsumerHealth #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA#Canada#Commonwealth#CorporateDivestitures #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Nelson Advisors @ 2026 Events Digital Health Rewired > March 2026 > Birmingham, UK NHS ConfedExpo > June 2026 > Manchester, UK HLTH Europe > June 2026, Amsterdam, Netherlands HIMSS AI in Healthcare > July 2026, New York, USA Bits & Pretzels > September 2026, Munich, Germany World Health Summit 2026 > October 2026, Berlin, Germany HealthInvestor Healthcare Summit > October 2026, London, UK HLTH USA 2026 > October 2026, USA Barclays Health Elevate > October 2026, London, UK Web Summit 2026 > November 2026, Lisbon, Portugal MEDICA 2026 > November 2026, Düsseldorf, Germany Venture Capital World Summit > December 2026 Toronto, Canada Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, MedTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies.www.nelsonadvisors.co.uk

Nelson Advisors: From Palantir to Payer: Why Vitruvian's $600 Million Bet on Angle Health Says Something Bigger About HealthTech Nine months ago, Angle Health closed what looked like a strong Series B. The San Francisco health benefits company raised $134 million in a mix of debt and equity led by Portage, bringing its total funding to just under $200 million. It was a respectable round for a company that most people outside the US employer benefits market had never heard of. Now, according to the Wall Street Journal, European mid market private equity firm Vitruvian Partners is leading a $600 Million investment in the same company. A round of that size, coming so soon after the last one, does not happen because a business is growing nicely. It happens because investors have decided that a company is becoming a category, and they want to own a meaningful piece of it before the price moves again. This article looks at what Angle Health actually does, why the small business health benefits market has become one of the most interesting corners of American healthcare, why a London headquartered growth investor is writing one of the largest cheques of the year into a US insurer and what the deal tells us about where HealthTech capital is heading as we move towards 2027. The company: an insurer built by data engineers Angle Health was founded by Ty Wang, its chief executive, and Anirban Gangopadhyay, both of whom previously worked as engineers at Palantir Technologies. That pedigree is not incidental. Palantir's core competence is integrating messy, siloed data from large organisations and turning it into operational decisions, and that is precisely the skill that the health insurance industry has historically lacked. Health insurance in the United States is, at its heart, a data business dressed up as a financial services business. The insurer collects premiums, predicts claims, prices risk and pays providers. Every one of those steps depends on information about members, their health, their utilisation patterns and the cost of the care they consume. The incumbents have that information, but it lives in decades-old claims systems, is processed in batches, and is used mainly to set prices once a year rather than to manage care continuously. Angle's founding insight was that a health plan built from scratch on modern data infrastructure could do the same job faster, cheaper and with more transparency. The company positions itself as an alternative payer for employers, bundling together the components that a small business would otherwise have to assemble from multiple vendors: the underlying medical plan, telehealth, behavioural health, care navigation and the administrative services that sit behind all of them. The product set gives a sense of the approach. Benefit Builder is an AI-driven quoting engine that can generate a firm, underwritten quote for a small employer in minutes rather than the days or weeks that a traditional carrier requires. Quote to Card automates implementation, so that a group that signs up can have members with active coverage almost immediately. Health Scorecard gives brokers and employers a view of the underlying risk in their population, something that has historically been a black box. Underneath these sits a proprietary risk model trained on millions of de-identified patient records, which is what allows the company to price groups quickly without taking on unacceptable underwriting risk. The numbers that accompanied the Series B in December 2025 were the kind that get growth investors' attention. Angle reported that it served more than 3,000 employers across 44 states, that its revenue had grown 26-fold since its 2022 Series A, that its median rate increases were 36 per cent lower than the small business industry average, that it retained more than 80 per cent of its customers at renewal and that member satisfaction was running at around 90 per cent. Whatever the exact metrics behind the new round, the trajectory from a $58 million Series A in early 2023 to a $134 million Series B to a $600 million growth round in under four years is remarkable by any standard. The market: 62 million employees and a broken product To understand why investors are willing to fund a company like Angle at this scale, you have to understand the market it is attacking. Small and medium sized businesses employ close to half of the American workforce, around 62 million people. Almost all of them who have health insurance get it through their employer, because that is how the American system works. But the small group insurance market is one of the least well-served segments of the entire healthcare economy. Large employers self-insure. They carry their own claims risk, hire a third-party administrator to process claims, and use their scale to negotiate directly with provider networks and pharmacy benefit managers. They have the data, the leverage and the sophistication to manage healthcare as a cost centre. Small employers have none of those things. They buy fully insured products from a handful of large carriers, typically through a broker, and they take whatever rate increase the carrier hands them each year. With employer healthcare costs projected to rise by around 6.7 per cent in 2026, the highest increase in over a decade, many small businesses face rate increases well into double digits. The result is a market in which the product is expensive, the buyer is unsophisticated, the distribution is intermediated by brokers with their own incentives, and the incumbents have very little reason to innovate because their customers have very few alternatives. It is, in other words, the kind of market that a data-native entrant can attack by offering a fundamentally better price, a faster buying experience and more transparency about where the money goes. That is the same logic that drove the first wave of "insurtech" health plans in the late 2010s. Oscar Health, Bright Health, Clover Health and others raised enormous sums on the premise that a tech-enabled insurer could out-compete the incumbents. Most of them struggled badly. Bright Health effectively collapsed. Clover was forced to restructure. Oscar survived and has since become profitable, but only after years of losses and a painful retrenchment. The lesson the market drew was that insurance is a scale business, medical loss ratios are unforgiving, and a nice app does not change the fundamental economics of paying for healthcare. Angle's proposition, and the reason investors are willing to back it after that history, is that it is attacking a different segment with a different model. It is not chasing the individual market or Medicare Advantage, where the first wave came unstuck. It is focused on small groups, where the incumbent product is weakest and where the ability to underwrite quickly and accurately is a genuine competitive advantage. And it is leading with the data and underwriting infrastructure rather than with the consumer experience, which is arguably the lesson the first wave learned too late. The investor: why Vitruvian, and why now Vitruvian Partners is not a household name in healthcare, but it is one of the more interesting growth investors in Europe. Founded in London in 2006 by a group of former Apax and BC Partners executives, it has built a track record backing high-growth, technology-enabled companies across sectors, including Just Eat, Farfetch, Skyscanner, Trustpilot, Darktrace and Bitdefender. Its healthcare portfolio has historically leaned towards life sciences services and software rather than payers, with investments such as CRF Health in clinical trial technology. A $600 million round led by a European mid-market firm into an American health insurer is therefore notable on several counts. The first is size. Vitruvian's funds have grown substantially over its four fund generations, and its most recent vehicle gives it the capacity to lead rounds of this scale. But this is still an outsized commitment for a firm that has historically written cheques in the tens or low hundreds of millions. It signals conviction rather than diversification. The second is geography. European growth investors have been increasingly active in US HealthTech over the past few years, partly because the American market is where the largest healthcare revenue pools sit, and partly because valuations in Europe have not offered enough exit opportunities to justify the fund sizes being raised. Vitruvian leading a round of this size in San Francisco is a marker of that trend. The third is sector. Vitruvian's investment thesis has always been about businesses with strong network effects, high growth and defensible technology, and it has generally avoided regulated financial services and balance-sheet-heavy businesses. An insurer, even a technology-led one, carries underwriting risk and regulatory capital requirements. The fact that Vitruvian is comfortable with that profile suggests either that Angle's model is structured to keep balance-sheet risk manageable, for instance through reinsurance and level-funded products, or that the firm has concluded the data moat is strong enough to justify the exposure. The fourth is timing. Angle's Series B closed in December 2025. A $600 million round in September 2026 implies that the company's growth accelerated through the first half of the year, that the demand it saw from employers facing record cost increases translated into bookings, and that the founders and existing investors saw an opportunity to raise a war chest while capital markets were receptive. It also implies that this is as much a secondary and growth round as a pure primary raise; rounds of this size at this stage frequently include liquidity for early investors and employees, and it would not be surprising if some of Angle's seed and Series A backers took money off the table. What Angle will do with $600 million The obvious answer is grow. Angle serves employers in 44 states and, at the time of the Series B, had ambitions to expand that footprint. Health insurance is regulated state by state, and entering a new state requires licensing, network contracting and regulatory capital. A large round removes the constraint that would otherwise slow that expansion. The less obvious answer is that a company at this stage, with this much capital, starts to think about what it can own beyond its core product. There are three plausible directions. The first is vertical integration into care delivery. Angle already bundles telehealth and behavioural health into its plans. A payer that also controls the front door to care can manage utilisation far more effectively than one that simply pays claims. That is the logic behind the large incumbents' acquisitions of clinics, pharmacies and home health businesses, and there is no reason a well-funded challenger would not pursue a version of it. The second is horizontal expansion into adjacent benefits. Small employers do not only buy health insurance. They buy dental, vision, life, disability and increasingly financial wellness products, and they buy them through the same brokers. A platform that has solved the quoting, underwriting and implementation problem for medical can extend that to other lines relatively cheaply, and doing so raises the switching cost for the employer. The third is acquisition. A company with $600 million of fresh capital and an experienced private equity investor on its board is in a position to buy. The obvious targets would be regional third-party administrators, care navigation businesses, benefits administration software, and smaller alternative health plan operators whose books of business could be migrated onto Angle's infrastructure. The small group benefits market is fragmented, and consolidation through a data-native platform is exactly the kind of play that a growth investor would underwrite. What this means for HealthTech more broadly Looking beyond Angle itself, the deal tells us several things about the state of HealthTech investment in the second half of 2026. Capital is concentrating in AI-native infrastructure rather than point solutions. The first decade of digital health investment funded thousands of apps, devices and services that sat on top of the existing system and tried to improve one piece of it. Most of them struggled to get paid, because the system they were bolted onto had no incentive to pay them. The companies now attracting the largest rounds are the ones rebuilding the underlying infrastructure of healthcare finance and operations: the payer, the revenue cycle, the clinical documentation layer, the claims engine. Angle is a payer built as a data company, and that is why it is being valued like a software business rather than an insurance business. The "AI" label matters less than the data asset. Every HealthTech company now describes itself as AI-native, and investors have become appropriately sceptical of the term. What distinguishes Angle is not that it uses machine learning, which every insurer does, but that it has accumulated a proprietary dataset on millions of patients and a real-time claims flow across thousands of employers, and that its entire operating model is built to feed that data back into pricing and care management. The AI is the output of the data asset, not the other way round. Investors who understand this are increasingly willing to pay for the data flywheel and increasingly unwilling to pay for the model alone. The employer channel is back in favour. For much of the past five years, the smart money in US HealthTech has flowed towards value-based care and Medicare Advantage, where government reimbursement created a large and predictable revenue pool. That trade has become considerably harder as reimbursement rates have tightened and the regulatory environment has become more hostile. The employer market, and particularly the small employer market, is emerging as the alternative: it is enormous, it is under-served, it is facing the sharpest cost increases in a decade, and the customer has a direct financial incentive to switch to something better. European investors are becoming serious participants in US HealthTech at the growth stage. Vitruvian is not alone. European growth and buyout firms have been steadily increasing their exposure to American healthcare technology, drawn by the size of the market and the scarcity of comparable opportunities at home. The reverse flow, of US capital into European HealthTech, has been the story for the past decade. This deal is one of the clearer signals yet that the traffic is starting to move in both directions. The risks It would be a mistake to treat a round of this size as validation of the model. Rounds of this size are bets, and this one carries real risk. The most obvious risk is the one that undid the first wave of insurtech: medical loss ratios. A health plan that grows quickly by offering lower premiums than the incumbents will, at some point, discover whether its underwriting was as good as its models suggested. If Angle's risk prediction is genuinely better than the incumbents', it will be able to price below them and still make money. If it is not, rapid growth simply means accumulating unprofitable risk faster. The 36 per cent lower rate increases the company reported are impressive, but they are also exactly what a plan that had under-priced its risk would show in the early years. The second risk is regulatory. State insurance regulators have become more attentive to fast-growing alternative health plans, particularly those that use level-funded or self-funded structures to reduce their regulatory capital requirements. Any change in how those products are treated could affect the economics significantly. The third risk is competition. The large incumbent carriers are not standing still, and they have the balance sheets, the provider networks and the broker relationships to defend their small group books if they choose to. The more successful Angle becomes, the more likely it is to provoke a response. The fourth risk is the one that always attends rounds of this size: valuation. Whatever price Vitruvian is paying, it is one that assumes several more years of very rapid growth. Growth investors have been burned before in HealthTech by paying for trajectories that flattened, and a $600 million cheque leaves very little room for the trajectory to disappoint. Predictions With those caveats, some predictions about where this goes. Angle will make at least one significant acquisition within eighteen months. The capital, the investor and the market structure all point in that direction. The most likely target is a regional benefits administrator or an alternative health plan whose book can be moved onto Angle's platform. The small group employer market will attract at least two more growth rounds of $250 million or more in the next twelve months, as investors who missed Angle look for the next platform in the space. Expect existing benefits and navigation companies to reposition themselves as AI-native payers to capture that interest. At least one large incumbent carrier will respond with a dedicated small-group product built on a faster quoting and implementation engine, either developed internally or acquired. The incumbents can afford to buy their way to parity, and the demand signal is now too loud to ignore. Angle will be discussed as an IPO candidate within two years. A company that has raised close to $800 million across successive rounds, with a European growth investor that has taken several portfolio companies public, is on the path to the public markets whether or not it gets there. The performance of Oscar Health as a listed company will be the benchmark against which it is judged. And more broadly, the next twelve months will bring further European growth capital into US HealthTech at the late stage. Vitruvian's deal will be read by its peers as proof that a European firm can lead a round of this scale in the American market, and several of them have the fund sizes to follow. Conclusion The story of Angle Health is, on one level, a simple one. Two engineers who learned at Palantir how to integrate data at scale applied that skill to one of the most inefficient products in American healthcare, and found a market of 62 million employees whose employers were desperate for an alternative. The growth from a $58 million Series A to a $600 million growth round in under four years is the result. On another level, it is a story about where healthcare technology is heading. The winners of the next cycle will not be the apps that sit on top of the system. They will be the companies that rebuild the system's infrastructure with data at the core, and that are willing to take on the regulated, balance-sheet-heavy parts of healthcare that the first generation of digital health avoided. Vitruvian's willingness to lead a $600 million round into a company that is, legally, an insurer is the clearest sign yet that growth investors have accepted that thesis. Whether Angle proves it right depends on whether the underwriting holds. But the bet has been placed and the rest of the market will now have to respond. Nelson Advisors > European HealthTech, MedTech, Digital Health Investment Banking Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, MedTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies.www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, industry trends, deal commentary, market analysis & predictions @ https://www.healthcare.digital Nelson Advisors publish Europe's Leading Healthcare Technology Investment Banking Newsletter every week, join 5000+ HealthTech and MedTech subscribers today! https://lnkd.in/e5hTp_xb Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards, corporates, venture capital and private investors to maximise shareholder value and investment returns.www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech#MedTech#DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #FemTech#ConsumerHealth #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA#Canada#Commonwealth#CorporateDivestitures #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Nelson Advisors @ 2026 Events Digital Health Rewired > March 2026 > Birmingham, UK NHS ConfedExpo > June 2026 > Manchester, UK HLTH Europe > June 2026, Amsterdam, Netherlands HIMSS AI in Healthcare > July 2026, New York, USA Bits & Pretzels > September 2026, Munich, Germany World Health Summit 2026 > October 2026, Berlin, Germany HealthInvestor Healthcare Summit > October 2026, London, UK HLTH USA 2026 > October 2026, USA Barclays Health Elevate > October 2026, London, UK Web Summit 2026 > November 2026, Lisbon, Portugal MEDICA 2026 > November 2026, Düsseldorf, Germany Venture Capital World Summit > December 2026 Toronto, Canada Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, MedTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies.www.nelsonadvisors.co.uk

Nelson Advisors The End of the Outpatient Appointment in the NHS? The End of the Outpatient Appointment in the NHS? What Do The ‘Get On With It" Messages Mean for Primary Care, Hospitals and Healthcare Technology suppliers? Every year, the NHS in England delivers roughly 120 million outpatient appointments. Two thirds of them are follow-ups. And, according to the chair of NHS England, almost nobody in the system believes this is a sensible way to spend clinical time, patient time or public money. Speaking at the King's Fund last week, one year on from the publication of the 10 Year Health Plan, Penny Dash made a remark that will resonate with anyone who has spent time in health policy circles. At pretty much every conference she has attended in twenty years, she said, someone has stood up and declared that outpatients is an outdated model and that the NHS should get rid of it. And yet the volume keeps growing. Her conclusion was blunt: the time for saying it is over, and the time for doing it has arrived. That framing matters. It is not a new diagnosis, but it is a new tone. The chair of NHS England is no longer describing outpatient reform as an aspiration to be worked towards over a decade. She is describing it as a change that the system has already agreed on, and is now simply failing to execute. This post looks at what she actually said, why the outpatient model has proved so stubbornly resistant to reform, what the neighbourhood health and NHS Online agendas are designed to do about it, and what all of this is likely to mean for general practice, for patients and for the digital health companies that will be asked to build the new model. The scale of the problem The 120 million figure deserves a moment's reflection. Outpatient activity is by some distance the largest single category of planned hospital contact in England, dwarfing inpatient admissions and day cases. It has grown steadily for decades, faster than population growth, faster than the growth in GP consultations, and far faster than the growth in hospital capacity to deliver it. The reason two thirds of those appointments are follow-ups is structural rather than clinical. Once a patient enters a specialist pathway, the default is for the specialist to see them again. Follow-up intervals are set by habit and by risk aversion as much as by evidence. A consultant who discharges a patient back to their GP takes on a small reputational risk if something goes wrong; a consultant who books a six-month review takes on none. Multiply that asymmetry across every clinic in every trust and you arrive at a system in which tens of millions of appointments happen largely because the previous appointment happened. Dash's point was that this is not a good use of anyone's time. It is not a good use of the patient's time, who may take a half-day off work and travel across a city for a ten-minute conversation that could have happened by message or not at all. It is not a good use of clinical time, because the consultant reviewing a stable patient is not seeing a new patient on the waiting list. And it is a poor use of estate, because outpatient departments are among the most expensive real estate in the country to run for the value they generate. None of this is contested. The remarkable thing about the outpatient debate is how little disagreement there is on the diagnosis and how little progress has been made on the cure. Patient-initiated follow-up, advice and guidance, virtual clinics and remote monitoring have all been piloted, published and praised. Each has nibbled at the edges. None has bent the curve. Why the model has proved so hard to shift There are several reasons why an obviously inefficient model has survived twenty years of conference speeches calling for its abolition. The first is that the outpatient appointment is the unit of currency in which the hospital system counts, plans and is paid. Activity is commissioned in appointments. Waiting lists are measured in first appointments. Consultant job plans are built around clinic sessions. When the whole architecture of a system is denominated in a particular unit, it is extremely difficult to reduce the number of those units without appearing to reduce the amount of care being delivered. The second is that outpatients is where the boundary between primary and secondary care is negotiated, and that boundary is contested territory. From the hospital's point of view, a follow-up appointment is a way of keeping a patient under specialist supervision. From the GP's point of view, discharge back to primary care often means absorbing work without the resource to do it. The system has never resolved this tension, and so both sides have an incentive to keep the patient in the outpatient loop. The third reason, and the one Dash dwelt on most, is that the alternative to outpatients does not yet exist at scale. If the answer to "who looks after the patient with stable heart failure who no longer needs a cardiologist" is "a well-resourced, multidisciplinary community team with access to the patient's full record and a shared care plan", then that team has to be built first. In most of England it has not been. And this is where her comments on primary care come in. "Small, fragmented GP practices working in isolation" The most pointed passage of the speech was not about hospitals at all. It was about general practice. Dash reiterated a claim she has made before, that primary care has roughly twice the space it needs, and she went further in describing the current organisational model as unfit for the job the 10 Year Plan asks of it. Small, fragmented GP practices working in isolation, she said, are not a way to deliver a transformed emergency care pathway. They are not a way to deliver a transformed elective care pathway. And they are certainly not a way to deliver improvements in cardiovascular disease, other long-term conditions, or frailty and old age. Her use of the word "subscale" is worth noting. It is a term from corporate strategy rather than clinical practice, and it signals how NHS England's leadership now thinks about the sector. A subscale unit is one that is too small to achieve the efficiencies, the specialisation and the resilience that the market or the system demands. The implication is that the historic model of the independent contractor practice, serving a list of a few thousand patients from a converted house, is being described by the chair of NHS England as a structural problem to be solved rather than a tradition to be protected. The solution she set out is scale. GP practices need to be brought together with community services, mental health services and specialist services, working as integrated neighbourhood teams rather than as separate organisations passing patients between them. Everyone should have a care plan. Everyone should have a single patient record. Multidisciplinary working should be the norm rather than the exception. This is the neighbourhood health agenda, and it is the central organising idea of the 10 Year Plan. The plan's three shifts, from hospital to community, from analogue to digital and from sickness to prevention, all depend on there being a community model capable of absorbing the work. The outpatient reforms and the primary care reforms are therefore not two separate policies. They are two halves of the same policy. You cannot dismantle the outpatient follow-up unless there is somewhere for the patient to go, and Dash is arguing that the current shape of general practice is not that place. General practice will hear this differently. Many GPs would point out that they are already delivering more consultations than ever before, that the funding share of primary care has fallen over the past decade, and that "at scale" has in the past meant mergers and federations that added management cost without adding capacity. The claim about surplus estate has been particularly contentious, with practices arguing that the space is there because clinical rooms have to be available for a workforce that has not been funded. The "twice the space" figure will be interrogated closely, and the sector will want to see the analysis behind it. But the direction is unmistakable. The centre of NHS England has decided that the neighbourhood model requires organisational consolidation, and it is now saying so in public with increasing directness. NHS Online and the end of the referral If the neighbourhood reforms deal with the community end of the pathway, NHS Online deals with the hospital end. The new NHS "online hospital", due to launch in 2027, was described by Dash as a service that will move away from the concept of referrals and outpatients entirely. Instead, it will provide people with the advice they want and need very quickly. The initial scope is deliberately narrow. GPs will be able to refer patients, via the NHS App, to specialist clinicians anywhere in the country for a defined set of conditions. Those named so far include women's health symptoms pointing towards endometriosis and fibroids, and men's health presentations including prostate enlargement and raised PSA levels. The choice of conditions is telling. These are high-volume, often long-wait pathways in which the initial specialist input is largely a matter of history-taking, interpretation of results and decision-making about next steps rather than physical examination. They are the kind of clinical conversations that can happen asynchronously, at a distance, with a clinician who has spare capacity in Newcastle seeing a patient who would otherwise wait months in Norfolk. The deeper significance of NHS Online lies in three design choices. The first is that it is national. It decouples specialist capacity from geography, which is a direct challenge to the trust-based model in which each hospital serves its own catchment. The second is that it runs through the NHS App, which places the patient-facing front door of secondary care inside a platform that NHS England controls directly. The third, and the one Dash emphasised, is that it is framed as advice rather than as a referral. The patient is not being handed over to a specialist to be managed. They are getting a specialist opinion that flows back to the person who asked for it. There is a certain irony here that GPs will not have missed. The announcement of NHS Online, which will let GPs refer to specialists across the country, arrives at a moment when many GPs report increasing resistance to their referral activity from local systems. NHS England denies that GPs' ability to refer has changed, but the perception on the ground is of tighter triage, more referrals being bounced back, and more pressure to manage within primary care. Whether NHS Online opens a new door or merely reroutes patients away from local hospitals will depend entirely on how it is commissioned and how its capacity is funded. Data, records and the plumbing of reform Underneath all of this sits a simple technical precondition that Dash stated plainly: single patient records for everybody. It is impossible to run a neighbourhood team, dismantle follow-up appointments or deliver a national online specialist service if the clinician at each point in the pathway cannot see what happened at the previous point. The reason outpatient follow-ups persist is partly that the consultant does not trust that anyone else will see the patient's results. The reason GPs are wary of discharge is partly that they do not have visibility of the specialist's plan. The single patient record is the mechanism that is supposed to make trust possible. The NHS has been promising a single record for as long as it has been promising to abolish outpatients, and with a similar track record of delivery. But there are grounds for thinking this time is different. The NHS App has become a genuine mass-market platform. The federated data platform, whatever one thinks of its procurement, exists and is being adopted. The political commitment to the single patient record has been restated at the highest level, and the 10 Year Plan ties it explicitly to the care plan concept Dash described. If everyone is to have a care plan, then the plan has to live somewhere that everyone can see it. For the digital health sector, this is the layer where the commercial opportunity is most concrete. The neighbourhood model needs population health tooling to identify who needs a care plan. It needs shared care planning software that works across organisational boundaries. It needs remote monitoring to replace the follow-up appointment with continuous data. It needs triage and clinical decision support to make NHS Online safe at scale. And it needs integration, because the single patient record will in practice be assembled from many systems rather than replaced by one. Predictions: where this goes next The speech was a statement of intent rather than a policy announcement, but the intent was clear enough to support some reasonable predictions about the next three to five years. Outpatient follow-up volumes will finally start to fall, but slowly and unevenly. The combination of patient-initiated follow-up targets, remote monitoring and a shift in the payment model away from activity will begin to reduce the two-thirds follow-up share. The first movers will be the specialties where the follow-up is most obviously administrative, such as stable long-term conditions with a clear biomarker. The specialties where the clinician's physical presence adds real value will be the last to change. Expect the headline 120 million figure to be revisited as a benchmark in every future speech on the subject, and expect the first year in which it drops to be treated as a major milestone. General practice will consolidate, whether or not it wants to. The language of "subscale" is not accidental. The neighbourhood contracts, the estates review and the funding model will all be designed to favour practices that operate as part of larger integrated units. Some of this will happen through mergers, some through the growth of at-scale providers, and some through the migration of GPs into salaried roles within neighbourhood organisations. The independent contractor model will survive in name, but its share of the workforce and the population will shrink. Expect this to be one of the most contested workforce and contractual stories of the decade, and expect the "twice the space" claim to be the flashpoint around which the estates argument is fought. NHS Online will expand its scope faster than its initial launch suggests. Starting with a handful of gynaecology and urology pathways is prudent, but the logic of a national, app-based specialist advice service does not stop there. Dermatology, with its reliance on images, is an obvious next candidate. So are the management of stable cardiovascular conditions, diabetes reviews, and much of routine mental health follow-up. By the end of the decade NHS Online is likely to be handling a meaningful share of what is currently first-appointment outpatient activity, and the political question will shift from whether it works to whether it is hollowing out local hospitals. The referral itself will become a contested concept. NHS Online is framed as advice rather than referral, and that framing will spread. Advice and guidance, already widespread, will become the default first step for most non-urgent specialist input. GPs will increasingly find that the route to a specialist runs through a triage layer, digital or human, that decides whether a face-to-face appointment is warranted. That will reduce hospital demand, but it will also intensify the tension Dash's speech touched on, in which GPs feel their clinical judgement about who needs a specialist is being second-guessed by the system. The single patient record will be delivered incrementally rather than as a single event. There will not be a day on which every citizen has one record. There will instead be a widening set of data that flows into the NHS App and into shared care records, with the care plan becoming the object that different organisations contribute to. Progress will be measured by how many neighbourhood teams can see the whole record rather than by whether the architecture is complete. And finally, the HealthTech market will reorganise around the neighbourhood as the unit of purchase. For the past decade, digital health companies selling into the NHS have targeted trusts, integrated care boards, or individual practices. The neighbourhood, a population of perhaps thirty to fifty thousand served by an integrated team, is a new kind of customer. It is small enough to move quickly and large enough to justify real investment. Companies whose products only work within a single organisational boundary will struggle. Companies that can demonstrate value across the primary, community and specialist interface will find themselves selling into the most important growth segment in the system. What this means for HealthTech investors and founders For those of us who spend our time looking at the digital health market, the strategic signal from Dash's speech is one of demand creation. When the chair of NHS England says the system must "get on" with dismantling a 120-million-appointment-a-year model and replacing it with something that does not yet exist, she is describing a very large amount of work that will need to be enabled by technology. The most defensible positions will be in the workflow layer that makes the new model function: care planning, population segmentation, remote monitoring integrated with clinical pathways, asynchronous specialist advice, and the interoperability infrastructure that stitches the single record together. The riskiest positions will be in point solutions that replicate the old model in digital form, such as video outpatient appointments that simply move the follow-up onto a screen without questioning whether it should happen at all. There is also a consolidation story in the supplier base that mirrors the consolidation story in general practice. If the NHS is going to buy at neighbourhood and system scale, it will want fewer, broader vendors capable of supporting an integrated model rather than dozens of narrow tools. That will drive M&A activity among digital health companies, particularly those with strong primary care footholds that lack community or specialist capability, and vice versa. The next two years are likely to see a wave of combinations as suppliers position themselves for the neighbourhood contracts that will follow the 2027 launch of NHS Online and the rollout of integrated neighbourhood teams. Conclusion Penny Dash's speech at the King's Fund said nothing that health policy audiences had not heard before. That was, in a sense, her point. The outpatient model has been declared outdated for twenty years. General practice has been told it needs to work at scale for almost as long. The single patient record has been promised since the early days of the NHS IT programme. What has changed is not the analysis but the willingness of the system's leadership to say, publicly and repeatedly, that the analysis is settled and the delay is now the problem. Whether the 10 Year Plan succeeds where its predecessors failed will depend on execution rather than intent. The neighbourhood model has to be built before the outpatient model can be dismantled. General practice has to be brought along rather than simply reorganised. NHS Online has to earn the trust of both the GPs who refer into it and the patients who use it. And the data infrastructure has to work, reliably and at scale, in a system that has rarely managed that before. But the direction is set, and it is set with unusual clarity. The NHS is moving away from the appointment as its unit of care, away from the isolated practice as its unit of primary care organisation, and away from the referral as its mechanism for accessing specialist expertise. For clinicians, that is a profound change in how they work. For patients, it should be a profound change in how much of their lives they spend waiting. And for the technology companies that will build the new model, it is the clearest statement of demand the NHS has made in a generation. Nelson Advisors > European HealthTech, MedTech, Digital Health Investment Banking Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, MedTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies.www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, industry trends, deal commentary, market analysis & predictions @ https://www.healthcare.digital Nelson Advisors publish Europe's Leading Healthcare Technology Investment Banking Newsletter every week, join 5000+ HealthTech and MedTech subscribers today! https://lnkd.in/e5hTp_xb Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards, corporates, venture capital and private investors to maximise shareholder value and investment returns.www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech#MedTech#DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #FemTech#ConsumerHealth #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA#Canada#Commonwealth#CorporateDivestitures #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Nelson Advisors @ 2026 Events Digital Health Rewired > March 2026 > Birmingham, UK NHS ConfedExpo > June 2026 > Manchester, UK HLTH Europe > June 2026, Amsterdam, Netherlands HIMSS AI in Healthcare > July 2026, New York, USA Bits & Pretzels > September 2026, Munich, Germany World Health Summit 2026 > October 2026, Berlin, Germany HealthInvestor Healthcare Summit > October 2026, London, UK HLTH USA 2026 > October 2026, USA Barclays Health Elevate > October 2026, London, UK Web Summit 2026 > November 2026, Lisbon, Portugal MEDICA 2026 > November 2026, Düsseldorf, Germany Venture Capital World Summit > December 2026 Toronto, Canada Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, MedTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies.www.nelsonadvisors.co.uk

Nelson Advisors: Celebrities Are Investing in HealthTech - 10 Trends Attracting Money and Attention The convergence of high profile investment and digital health reflects a fundamental shift in medical care: transitioning from reactive, episodic treatment to continuous, predictive and consumer centric health management. High net worth cultural figures, particularly elite athletes such as Cristiano Ronaldo and LeBron James, alongside cultural entrepreneurs like Gwyneth Paltrow, are shifting their capital from traditional lifestyle endorsements to equity stakes in deep diagnostic and wellness platforms. 1. The Commercial and Cultural Catalysts of Celebrity Capital High profile public figures have historically aligned with consumer lifestyle brands through transactional endorsements. The migration toward HealthTech equity investment signals a structural evolution driven by functional alignment and distribution power. Authentic Functional Alignment: Elite athletes routinely manage their careers through data-driven physiological interventions, partnering with performance scientists to optimise recovery, cardiac efficiency, and metabolic output. Investing in platforms like WHOOP represents an extension of their daily operational routines rather than an artificial product alignment. Asymmetric Distribution Advantages: Celebrity investors solve one of early-stage health tech's steepest hurdles: customer acquisition costs. A global athlete or cultural icon can introduce complex diagnostic tools to hundreds of millions of followers, converting specialised performance metrics into mainstream consumer necessities. Syndicated Capital Structures: Funding structures increasingly unite disparate investor classes. WHOOP’s 2026 funding round (valuing the firm at $10.1 billion) integrated elite athletes (Ronaldo, James, Rory McIlroy) with global medical leaders such as Abbott and the Mayo Clinic. Similarly, Neko Health, founded by Spotify co-founder Daniel Ek and Hjalmar Nilsonne, blends tech founders with entertainment figures like Claudia Schiffer, Jimmy Iovine, Maria Sharapova and Thierry Henry. This capital mix grants startups clinical credibility alongside cultural visibility. 2. Paradigm Shift: Continuous Monitoring vs. Episodic Sick Care For over a century, traditional healthcare has operated under an episodic, reactive framework. Patients consult a physician only upon experiencing overt symptoms, generating sparse, siloed clinical snapshots (such as annual blood panels or isolated blood pressure checks). HealthTech replaces this fragmented model with continuous baseline tracking. Dynamic Baselines: Continuous consumer sensors measure metrics like heart rate variability (HRV), resting heart rate trends, skin temperature fluctuations and sleep architecture every night. Connecting Behaviour to Biology: Infrequent medical checkups offer little actionable feedback on daily habits. Continuous tracking connects immediate lifestyle choices, such as late night meals or intense training sessions, directly to autonomic nervous system recovery and physiological resilience. Contextualising Biomarkers: As continuous monitoring normalises physiological data, consumers increasingly rely on analytical software to contextualise results. Rather than waiting for an annual clinical consultation, individuals actively interrogate intermediate biomarkers, turning raw clinical data into personal health intelligence. 3. Sensor Sophistication and Diagnostic Data Synthesis The consumer sensor ecosystem has evolved beyond simple pedometers into comprehensive diagnostic suites capable of capturing multi-modal biometrics. Dimension First-Generation Devices Modern HealthTech Platforms Primary Metric Step counts, estimated active calories Autonomic recovery, continuous ECG, HRV, sleep staging Form Factor Bulky wristbands with digital screens Low-friction screenless straps, smart rings, non-invasive patches Analytical Scope Descriptive logging (what happened) Predictive interpretation (actionable adaptation recommendations) Data Breadth Isolated biomechanical movement Aggregated full-body scans, blood chemistry, and continuous metrics Modern platforms understand that individual biomarkers viewed in isolation can mislead. A spike in resting heart rate can indicate overtraining when viewed alongside athletic exertion, or an impending viral infection when paired with systemic inflammatory markers. Platforms such as Neko Health aggregate full body medical imaging, systemic blood analysis and wearable metrics from Apple Watch, Oura, and WHOOP into a unified record. This multi-modal synthesis breaks down historical data silos, assembling disparate metrics into a comprehensive biological profile. 4. AI Driven Interpretation and the Expansion of Consumer Wellness Continuous sensors and body scanners yield millions of discrete data points per user annually, an information volume that overwhelms both individual consumers and primary care physicians constrained by standard 15 minute appointments. Artificial intelligence functions as the connective tissue that translates raw data into structured insights. Pattern Recognition at Scale: AI engines process high-dimensional health data, converting raw overnight cardiac data into practical summaries (e.g., flagging poor recovery resulting from late-night metabolic disruption). While a human performance coach can guide dozens of athletes, an algorithmic model scales tailored physiological feedback to millions of users simultaneously. Digital Mental Health Ecosystems: The consumerisation of health extends into mental and emotional well-being. Platforms offering meditation, mindfulness, and on demand therapy bridge the gap caused by extensive clinical waiting lists and persistent stigma. By providing low-barrier, round the clock entry points, mobile platforms normalise routine mental health maintenance. Convergence of Beauty, Skin, and Systemic Health: AI powered visual recognition transforms mobile cameras into dermatological scanners capable of evaluating pigmentation, hydration and skin barrier health over time. Investors like Gwyneth Paltrow (via Kinship Ventures) have targeted this intersection. Because skin reflects systemic stress, sleep deprivation, and hormonal fluctuations, beauty tech is rapidly merging with metabolic and recovery tracking. 5. Longevity, Proactive Screening and the Consumerised Experience Consumer priorities are moving beyond simple lifespan extension toward expanding healthspan, the duration of life spent free from debilitating chronic illness. Preventive Early Interception: Cardiovascular diseases, metabolic dysfunctions, and solid tumors develop over years before producing outward symptoms. Preventive screening technologies detect subclinical changes early, when lifestyle and pharmacological interventions are least invasive and most cost-effective. Hospital vs. Consumer-Grade Design: Traditional healthcare infrastructure is often slow, fragmented, and bureaucratic. Platforms like Neko Health deliberately reconstruct clinical diagnostics around the user experience. By replacing cold, clinical environments with modern physical clinics, delivering rapid diagnostic turnarounds, and providing same-day physician consultations, these services frame proactive screening as an appealing consumer routine rather than an intimidating hospital ordeal. 6. Clinical Integration, Regulatory Boundaries and Sector Risks As consumer wellness tools adopt medical-grade diagnostics, the boundary between consumer gadgets and regulated healthcare services is narrowing. This transition brings significant regulatory, operational, and clinical hurdles. Diagnostic Overload and Incidental Findings: Increasing the volume of personal health data does not automatically improve health outcomes. Routine, broad-spectrum screening of asymptomatic populations risks uncovering benign anomalies ("incidentalomas"), triggering diagnostic anxiety, unnecessary follow-up procedures, and higher healthcare costs. Clinical Validation vs. Wellness Marketing: Consumer wearables frequently capture data with proprietary algorithms that have not undergone peer-reviewed clinical validation. Medical practitioners are cautious about basing therapeutic decisions on unverified consumer data. Strategic alliances between wearable startups and institutions like Abbott and the Mayo Clinic aim to bridge this validation divide through clinical trials and regulatory reviews across the US, UK, and EU. Clear Diagnostic Boundaries: Leading consumer platforms must carefully distinguish between automated lifestyle feedback and formal clinical diagnoses. AI-driven alerts can flag irregular rhythms or sleep disturbances, but they cannot replace licensed medical judgment. Regulators actively scrutinise these systems to ensure consumer-facing interfaces do not misrepresent automated insights as regulated medical advice. Key Takeaways HealthTech is undergoing a permanent transformation: Celebrity Capital as an Accelerator: High-profile investment provides essential cultural translation, converting specialised elite performance science into accessible consumer products. From Data Collection to Data Interpretation: The hardware value proposition has matured; future market value centres on multi-modal data integration, predictive AI modelling, and actionable user feedback. Consumer Standards in Healthcare: Modern health platforms succeed by replacing inefficient clinical interactions with intuitive, on-demand, and transparent digital first experiences. The Validation Imperative: Long-term market leaders will be distinguished by rigorous clinical validation, clear regulatory compliance, and the ability to demonstrate sustained, measurable improvements in user health outcomes. Nelson Advisors > European HealthTech, MedTech, Digital Health Investment Banking Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, MedTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies.www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, industry trends, deal commentary, market analysis & predictions @ https://www.healthcare.digital Nelson Advisors publish Europe's Leading Healthcare Technology Investment Banking Newsletter every week, join 5000+ HealthTech and MedTech subscribers today! https://lnkd.in/e5hTp_xb Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards, corporates, venture capital and private investors to maximise shareholder value and investment returns.www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech#MedTech#DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #FemTech#ConsumerHealth #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA#Canada#Commonwealth#CorporateDivestitures #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Nelson Advisors @ 2026 Events Digital Health Rewired > March 2026 > Birmingham, UK NHS ConfedExpo > June 2026 > Manchester, UK HLTH Europe > June 2026, Amsterdam, Netherlands HIMSS AI in Healthcare > July 2026, New York, USA Bits & Pretzels > September 2026, Munich, Germany World Health Summit 2026 > October 2026, Berlin, Germany HealthInvestor Healthcare Summit > October 2026, London, UK HLTH USA 2026 > October 2026, USA Barclays Health Elevate > October 2026, London, UK Web Summit 2026 > November 2026, Lisbon, Portugal MEDICA 2026 > November 2026, Düsseldorf, Germany Venture Capital World Summit > December 2026 Toronto, Canada Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, MedTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies.www.nelsonadvisors.co.uk

Te Papa Hauora: Christchurch's Health Precinct Emerges as a $1 Billion Plus HealthYech Hub Fifteen years after a series of devastating earthquakes flattened much of its central city, Christchurch has quietly assembled something few cities its size can claim: a single, walkable precinct where a major public hospital, three tertiary institutions, a growing cluster of medical device and digital health startups, and hundreds of millions of dollars in new construction all sit within a few blocks of one another. It is called Te Papa Hauora, the Christchurch Health Precinct and what began as a rebuilding project after the 2010–2011 Canterbury earthquakes has evolved into something closer to a deliberate industrial strategy. Cumulative investment across its public hospital rebuilds, university and polytechnic campuses, and commercial healthtech space now runs well past the billion dollar mark and the momentum is starting to attract attention well beyond New Zealand's shores. That is a striking outcome for a city of roughly 400,000 people on the edge of the South Pacific, and it did not happen by accident. It is the product of a rare alignment: a health system, a research sector and a construction boom that were all forced to rebuild from the ground up at the same time and a set of institutions that chose to rebuild together rather than apart. Rebuilding as a strategy, not just a necessity The Canterbury earthquakes destroyed or condemned large parts of Christchurch's hospital and university infrastructure, including buildings around Christchurch Hospital itself. The funding that followed came from an unusual combination of sources rarely seen together at this scale: Crown appropriations directed through the post-quake recovery agencies, insurance settlements on damaged and demolished buildings, and ordinary university and district health board capital budgets, all landing in the same few years and all needing to be spent on replacement infrastructure somewhere. Faced with the need to replace tens of thousands of square metres of clinical, teaching, and research space regardless, the city's health and education leaders made a consequential decision: instead of scattering replacement buildings across the city as insurance settlements and government funding allowed, they would concentrate them on and around the existing hospital campus in the central city, on Riverside land along the Avon River, within easy walking distance of the CBD. The result, formalised as Te Papa Hauora, is a strategic partnership between Health New Zealand | Te Whatu Ora Waitaha Canterbury, the University of Canterbury, the University of Otago, Ara Institute of Canterbury, and mana whenua representation through Ngāi Tūāhuriri. Rather than a single building or a single funder, the precinct is a coordinated campus plan spanning roughly two dozen individual sites and facilities, anchored by Christchurch Hospital and Christchurch Women's Hospital, and built out over more than a decade. The scale of individual components gives a sense of how the totals add up. The Christchurch Hospital Outpatients Building, a 10,500 square metre facility housing 27 outpatient services under one roof, was delivered for NZ$72 million and opened in 2019, ten percent under budget. The broader Acute Services Building program, encompassing new operating theatres, an expanded intensive care unit, a new emergency department, a state of the art radiology department and around 400 beds, formed part of a NZ$650 million government investment across the Christchurch and Burwood hospital campuses. More recently, the Waipapa Acute Services Building has been growing again: a new Tower C is adding a further 16,000 square metres and eventually 160 inpatient beds to the existing 62,000 square metre facility, with construction due to finish in late 2026 and clinical operations beginning in early 2027. Layer on top of that the education and research infrastructure. Manawa, the purpose-built health education and simulation building that opened in 2018 opposite Christchurch Hospital, now serves more than 2,000 students and staff across Ara Institute of Canterbury, the University of Canterbury, and Health New Zealand, complete with a simulation floor replicating operating theatres and hospital wards, and radiation-free virtual x-ray training technology. The University of Otago's Christchurch campus has its own redevelopment underway, due for completion in early 2026 and designed to serve more than 1,000 students and 500 staff. Add the ordinary churn of commercial property in and around the precinct, new office buildings built for health-sector tenants have been changing hands on Christchurch's commercial property market, a sign that private investors, not just government agencies and universities, now see durable value in owning space inside the precinct's boundary and a headline figure north of a billion dollars in cumulative capital deployed becomes entirely plausible, without needing to inflate any single number to get there. From rebuild to research and innovation hub What distinguishes Te Papa Hauora from an ordinary hospital redevelopment is what has grown up around the construction rather than because of it. Christchurch has become an outsized centre of gravity for New Zealand's health technology sector: the city is now home to roughly 26% of the country's healthtech companies, a sector that generates an estimated NZ$520 million to NZ$650 million in exports and employs somewhere between 3,200 and 4,000 people regionally. For a city that represents a modest share of New Zealand's total population, that concentration is well out of proportion and Te Papa Hauora is a large part of the reason why. The precinct's founders have been explicit that co-location with a working, full-service public hospital and three tertiary institutions is the whole point. Clinicians, researchers, and company founders share a campus rather than an email address book, which shortens the distance between a clinical problem observed on a hospital ward and a prototype built to solve it. That proximity has produced a run of genuine commercial successes headquartered in or closely tied to Christchurch: Izon Science's mRNA and nanoparticle characterisation tools, BioOra's immunotherapy manufacturing facility, MARS Bioimaging's spectral, photon-counting CT scanning technology (a genuine world-first developed out of University of Canterbury physics research), SwalTech's dysphagia treatment devices, Medsalv's sustainable single-use device reprocessing, Canterbury Scientific's precision diagnostics, and digital health ventures such as oVRcome, which uses virtual reality for anxiety and phobia therapy. That commercial cluster has recently gained a dedicated home of its own. The Ōtautahi Christchurch Health Technology Centre, launched within the heritage buildings of Te Matatiki Toi Ora – The Arts Centre (seismically restored after the earthquakes and connected by the "Bridge of Aspiration"), sits on the edge of the health precinct proper and was established specifically to walk healthtech ventures from concept to commercialisation. It launched with eight founding tenant companies spanning a deliberately wide slice of the sector: Komodo and Myovolt in wearable and vibration-based therapeutic devices, oVRcome in virtual-reality mental health treatment, the Johner Institute in medical device regulatory and quality consulting, The Kite Programme and ContentedAI in digital and AI-enabled health tools, and The Honest Human and Calmly rounding out a group working on patient-facing wellbeing products. Housing regulatory consultants alongside device and software founders in the same heritage building is itself a statement of intent: the centre offers advisory support across the unglamorous but decisive parts of building a medtech company: regulatory affairs, quality systems, health economics, reimbursement strategy, and clinical research design. Positioning that expertise a short walk from Christchurch Hospital's clinicians and from university researchers is a deliberate attempt to compress the notoriously long and expensive path from device idea to regulatory approval to reimbursed clinical use. Why international investors are starting to pay attention None of this would matter much to anyone outside New Zealand if it were simply a well organised domestic hospital campus. What has changed in the past couple of years is that Christchurch has started actively positioning the precinct as an export proposition, a place where international medtech, diagnostics, and digital health companies can validate products, run trials, and manufacture at a materially lower cost than in the United States, Europe, or Australia, while still operating inside a well regulated, English speaking, OECD healthcare system. That positioning rests on a few concrete advantages that resonate with the calculus of an offshore investor or corporate development team. New Zealand's healthcare system, hospital infrastructure, and regulatory environment are internationally credible without carrying the cost structure of a Boston, Zurich, or Singapore. A single, geographically compact hospital and university campus means clinical validation studies can recruit patients, secure ethics approval, and access specialist clinicians without the logistical sprawl that dogs equivalent projects in larger countries. Christchurch's own economic development agency has begun explicitly marketing the city as a place to "deliver immunotherapy treatment more safely, cheaply and effectively," and as a clinical validation hub for medical devices, diagnostics, and health technology more broadly, language pitched squarely at offshore companies weighing where to run a trial or set up a validation partnership, not just at domestic founders. The city's broader case for foreign capital reinforces the specific healthtech pitch. Christchurch sits within reach of the deep-water port at Lyttelton and the Port of Timaru, has its own international airport for direct freight and passenger connections, and draws talent from three universities, Canterbury, Otago, and Lincoln alongside support organisations such as Ministry of Awesome and the Centre for Entrepreneurship that feed graduates and spinouts into the local startup ecosystem. Add a cost of living and cost of operating that undercuts comparable innovation hubs in Australia, the UK and the US West Coast, and the pitch to an international investor becomes straightforward: access first-world clinical infrastructure and regulatory credibility at a fraction of the capital intensity required elsewhere. There is a regulatory dimension to the pitch as well. New Zealand's medicines and medical device regulator, Medsafe, has a long standing reputation for pragmatic, timely assessment relative to larger regulators, and New Zealand's clinical trial approval processes are frequently cited by international sponsors as faster and less bureaucratic than equivalent pathways in the US or EU, without any corresponding loss of data quality or ethical rigour. For an offshore diagnostics or device company trying to generate credible early clinical evidence before committing to the far larger cost of an FDA or CE mark pathway, running that first study inside a single, well-instrumented hospital campus in a jurisdiction known for turning trial applications around quickly is a meaningfully different proposition than doing the same work across a fragmented, multi-site health system elsewhere. Commercial property activity inside the precinct is one of the more concrete tells that this pitch is landing. New office buildings purpose-built for health-sector and health-tech tenants within the precinct's footprint have been transacting on the open commercial property market rather than sitting exclusively in government or university ownership, the kind of investor behaviour that typically follows, rather than leads, genuine confidence in a location's medium-term prospects. It is a quieter signal than a headline foreign direct investment announcement, but arguably a more durable one: institutional property investors do not typically buy into a precinct on the strength of a press release. The Waipapa expansion as a forward signal The timing of the Waipapa Tower C expansion matters for how the precinct's investment story is likely to develop over the next few years. Rather than treating the post-earthquake rebuild as a one off, finished event, Health New Zealand is actively adding acute capacity on the same campus footprint, 16,000 additional square metres and up to 160 further inpatient beds, with two ward floors of 64 beds being fitted out now and three further floors built as shell space for future expansion as demand requires. That shell-space design is itself a signal: the health system is planning for the precinct to keep growing well beyond 2027, rather than treating current capacity as an endpoint. For companies and investors evaluating Christchurch, an expanding rather than static hospital campus changes the calculation. A health precinct that is visibly still under construction, with major acute-care capacity coming online as recently as 2026 and 2027, offers a longer runway of co-location opportunities, procurement relationships, and clinical trial capacity than one where the building program wrapped up years ago. It also suggests the public capital commitment behind the precinct is not a sunk, one-time cost but an ongoing one, a detail that matters to anyone assessing whether Te Papa Hauora's advantages will still exist in five or ten years. What Christchurch still needs to prove None of this guarantees Te Papa Hauora becomes the durable, internationally significant healthtech hub its boosters describe. New Zealand's home market is small, meaning almost every company that grows out of the precinct must export from day one, adding a layer of commercial complexity that comparably positioned clusters in larger domestic markets do not face to the same degree. Capital availability is a persistent constraint too: New Zealand's venture capital market is thin relative to the capital intensity that medical device and diagnostics companies typically require to reach regulatory approval and scale, which is precisely why the precinct's pitch to offshore investors and corporate partners matters as much as it does, the ambition assumes international capital will do work that the domestic market cannot. There is also the ordinary discipline of major public infrastructure delivery to contend with. Hospital construction projects of this scale, in New Zealand as everywhere else, are vulnerable to cost escalation, contractor capacity constraints, and the kind of scheduling slippage that has affected other Health New Zealand infrastructure programs around the country. The fact that the Outpatients Building came in under budget is a good early sign; it is not a guarantee that every subsequent stage of the precinct's build-out will follow the same pattern. A model worth watching What makes Te Papa Hauora interesting is not any single building, company, or investment figure, it is the underlying model. A mid-sized city used a forced, earthquake-driven rebuild as an opportunity to co-locate its hospital, its universities, and its emerging health-tech sector on one compact campus, then built the institutional scaffolding, shared governance through Te Papa Hauora, a dedicated technology centre for commercialisation support, an explicit international marketing pitch around cost-effective clinical validation needed to turn physical proximity into commercial advantage. The billion-dollar-plus capital figure gets the headlines, but the more consequential number may be the 26% of the country's healthtech companies now choosing to build in a single New Zealand city, drawn there by exactly the kind of proximity and infrastructure that a purpose built precinct, rather than a series of disconnected rebuild projects, was designed to create. Whether Christchurch converts that early momentum into a genuinely globally significant health-innovation cluster, on the scale of a Kendall Square or a Cambridge Biomedical Campus, even at a fraction of the size, will depend on the things every emerging hub eventually has to prove: that the capital keeps flowing after the novelty wears off, that a small domestic market does not cap the ambitions of the companies growing up inside it, and that the international investors currently taking a closer look decide the numbers, once they run them properly, still add up. For now, the precinct has done the harder and less glamorous part first, building the physical and institutional infrastructure and is only just beginning to make its case to the world. Nelson Advisors > European HealthTech, MedTech, Digital Health Investment Banking Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, MedTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies.www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, industry trends, deal commentary, market analysis & predictions @ https://www.healthcare.digital Nelson Advisors publish Europe's Leading Healthcare Technology Investment Banking Newsletter every week, join 5000+ HealthTech and MedTech subscribers today! https://lnkd.in/e5hTp_xb Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards, corporates, venture capital and private investors to maximise shareholder value and investment returns.www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech#MedTech#DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #FemTech#ConsumerHealth #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA#Canada#Commonwealth#CorporateDivestitures #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Nelson Advisors @ 2026 Events Digital Health Rewired > March 2026 > Birmingham, UK NHS ConfedExpo > June 2026 > Manchester, UK HLTH Europe > June 2026, Amsterdam, Netherlands HIMSS AI in Healthcare > July 2026, New York, USA Bits & Pretzels > September 2026, Munich, Germany World Health Summit 2026 > October 2026, Berlin, Germany HealthInvestor Healthcare Summit > October 2026, London, UK HLTH USA 2026 > October 2026, USA Barclays Health Elevate > October 2026, London, UK Web Summit 2026 > November 2026, Lisbon, Portugal MEDICA 2026 > November 2026, Düsseldorf, Germany Venture Capital World Summit > December 2026 Toronto, Canada Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, MedTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies.www.nelsonadvisors.co.uk